WO2014072956A1 - Oxazolidin-2-one-pyrimidine derivatives - Google Patents

Oxazolidin-2-one-pyrimidine derivatives Download PDF

Info

Publication number
WO2014072956A1
WO2014072956A1 PCT/IB2013/060052 IB2013060052W WO2014072956A1 WO 2014072956 A1 WO2014072956 A1 WO 2014072956A1 IB 2013060052 W IB2013060052 W IB 2013060052W WO 2014072956 A1 WO2014072956 A1 WO 2014072956A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkoxy
compound
amino
oxazolidin
trifluoromethyl
Prior art date
Application number
PCT/IB2013/060052
Other languages
French (fr)
Inventor
Robin Alec Fairhurst
Pascal Furet
Frank Stephan Kalthoff
Andreas Lerchner
Heinrich Rueeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to LTEP13795867.4T priority Critical patent/LT2922848T/en
Priority to AP2015008347A priority patent/AP2015008347A0/en
Priority to IN2912DEN2015 priority patent/IN2015DN02912A/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to DK13795867.4T priority patent/DK2922848T5/en
Priority to CA2890942A priority patent/CA2890942C/en
Priority to RS20170882A priority patent/RS56336B1/en
Priority to PL13795867T priority patent/PL2922848T3/en
Priority to ES13795867.4T priority patent/ES2641820T3/en
Priority to EP17157570.7A priority patent/EP3199158B1/en
Priority to CU2015000050A priority patent/CU24365B1/en
Priority to JP2015541289A priority patent/JP6262245B2/en
Priority to SG11201503447QA priority patent/SG11201503447QA/en
Priority to EA201590929A priority patent/EA027987B1/en
Priority to EP13795867.4A priority patent/EP2922848B1/en
Priority to BR112015010136A priority patent/BR112015010136A2/en
Priority to AU2013343022A priority patent/AU2013343022B2/en
Priority to MA38076A priority patent/MA38076A1/en
Priority to KR1020157011951A priority patent/KR102153763B1/en
Priority to MX2015005914A priority patent/MX363436B/en
Priority to NZ706591A priority patent/NZ706591A/en
Priority to UAA201502809A priority patent/UA114001C2/en
Priority to CN201380052670.1A priority patent/CN104718204B/en
Priority to SI201330782T priority patent/SI2922848T1/en
Publication of WO2014072956A1 publication Critical patent/WO2014072956A1/en
Priority to TNP2015000120A priority patent/TN2015000120A1/en
Priority to ZA2015/02175A priority patent/ZA201502175B/en
Priority to IL238239A priority patent/IL238239A/en
Priority to PH12015501053A priority patent/PH12015501053B1/en
Priority to CR20150248A priority patent/CR20150248A/en
Priority to HK15109748.9A priority patent/HK1209108A1/en
Priority to HRP20171425TT priority patent/HRP20171425T1/en
Priority to CY20171101014T priority patent/CY1119391T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3 kinases.
  • PI3K phosphatidylinositol-3-kinase
  • the phosphatidylinositol-3-kinases superfamily comprises 4 different PI3K related lipid or protein kinases.
  • Class I, II and III are lipid kinases that differ from their substrate specificities whereas class IV PI3K also called PI3-kinase-related protein kinase (PIKK) are protein kinases.
  • PIKK PI3-kinase-related protein kinase
  • Class I PI3Ks comprise a family of lipid kinases that catalyze the transfer of phosphate to the D-3' position of inositol lipids to produce phosphoinositol-3- phosphate (PIP), phosphoinositol-3,4-diphosphate (PIP 2 ) and phosphoinositol-3,4,5- triphosphate (PIP 3 ) that, in turn, act as second messengers in signaling cascades by docking proteins containing pleckstrin-homology, FYVE, Phox and other phospholipid- binding domains into a variety of signaling complexes often at the plasma membrane
  • the tumor suppressor gene PTEN which dephosphorylates phosphoinositides at the 3' position of the inositol ring and in so doing antagonizes PI3K activity, is functionally mutated or deleted in a variety of tumors (Keniry & Parsons, Oncogene 27:5477-5485 (2008)).
  • Some studies indicate that the failure to express PTEN can mediate a shift of signaling dependence from the PI3Ka to the ⁇ -isoform (Wee et al, Pore Natl Acad Sci USA 105:13057-13062 (2008)). Therefore, inhibition of both class I PI3K a and ⁇ -isoforms can be particularly advantageous in cancers that are deficient in PTEN phosphatase.
  • mTOR is a protein kinase and a member of the class IV PI3K.
  • mTORCI protein kinase
  • mTORC2 Activation of mTORCI is dependent on active PI3K and Akt kinases. Regulation of mTORC2 activation is more complex.
  • mTORC2 is responsible for enhancement of Akt kinase activity via phosphorylation of serine residue 473
  • Cutaneous squamous cell carcinoma represents the second most frequent human skin cancer, commonly preceded by actinic keratosis (AK).
  • AK actinic keratosis
  • the pathogenesis of AK and cutaneous SCC has been associated with chronic UV exposure as one major risk factor (Salasche, J Am Acad Dermatol 42: 4-7 (2000)).
  • An enhanced activity of PI3K/Akt/mTOR pathway has been suggested in a previous study (Chen et al., Br J Dermatol; 160 (2):442- 445 (2009)).
  • the invention relates to oxazolidin-2-one substituted pyrimidine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof,
  • R 1 is methyl, ethyl or hydroxymethyl
  • R 2 is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC 5 -alkoxy, hydroxy-C 2 -C 4 -alkoxy or Ci-C2-alkoxy-C 2 -C 4 -alkoxy for the para position,
  • pyridyl which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-rC 5 -alkoxy, hydroxy-C 2 -C 4 -alkoxy or C 1 -C 2 -alkoxy-C 2 -C 4 -alkoxy for the para position,
  • a 5 membered monocyclic heteroaryl containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F;
  • R 3 is H or methyl.
  • the term "compounds of the present invention” refers to compounds of formula (I) and subformulae thereof, salts of the compound, hydrates or solvates of the compounds and/or salts, as well as all stereoisomers (including diastereoisomers and enantiomers), tautomers and isotopically labeled compounds (including deuterium substitutions).
  • Compounds of the present invention further comprise polymorphs of compounds of formula (I) (or subformulae thereof) and salts thereof. Where compounds of formula (I) are mentioned, this is meant to include also the tautomers and N-oxides of the compounds of formula (I).
  • the compounds of formula (I) are considered suitable to be used in the treatment of diseases dependent on PI3 kinases.
  • the compounds of formula (I) are considered suitable, for example, to be used in the treatment of diseases dependent on class I PI3 kinase or dependent on class I PI3 kinase and mTOR.
  • alkoxy refers to a fully saturated branched, including single or multiple branching, or unbranched hydrocarbon moiety attached to the rest of the molecule via an -O- linking group. Unless otherwise provided, alkoxy refers to moieties having 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 7 carbon atoms, or 1 to 4 carbon atoms.
  • alkoxy examples include, but are not limited to, methoxy, ethoxy, n- propoxy, / ' so-propoxy, n-butyoxy, sec-butoxy, so-butoxy, iert-butoxy, n-pentoxy, isopentoxy, neopentyl, n-hexyloxy.
  • pyridyl refers to 2-pyridyl, 3-pyridyl or 4-pyridyl. Substituents in meta or para position are attached to a carbon atom of the pyridyl. A representative example is 3-pyridyl.
  • 5 membered monocyclic heteroaryl containing 2 to 3 heteroatoms selected from N, O or S are attached to a carbon atom of the heteroaryl.
  • Examples of 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S include, but are not limited to thiazolyl, oxazolyl, 1 ,2,4-oxadiazolyl, 1 ,3,4- oxadiazolyl and 1 ,3,4-thiadiazolyl.
  • a representative example is thiazolyl.
  • the invention provides a compound of the formula (I) and/or a pharmaceutically acceptable salt and/or a solvate thereof, selected from a compound of the formula (la)
  • R 1 and R 2 are as defined for a compound of formula (I) above.
  • the invention provides a compound of the formula (I) and/or a pharmaceutically acceptable salt and/or a solvate thereof, selected from a compound of the formula (lb)
  • R 1 and R 2 are as defined for a compound of formula (I) above.
  • the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 2 is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-pCs-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position.
  • the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 2 is pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-pCs-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position.
  • the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 2 is a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
  • the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 2 is phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 4-(3-hydroxypropoxy)-phenyl, 4- (2-hydroxyethoxy)-phenyl or 4-(2-methoxyethoxy)-phenyl.
  • the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 2 is 3-pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC 5 -alkoxy, hydroxy-C 2 -C 4 -alkoxy or Ci-C2-alkoxy-C 2 -C 4 - alkoxy for the para position.
  • the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 2 is 3-pyridyl.
  • the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein R 2 is thiazolyl, which is unsubstituted or substituted by 1 to 2 substituents
  • the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 2 is 2-thiazolyl which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
  • the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 2 is 2-thiazolyl
  • the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is methyl
  • the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is ethyl
  • the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is hydroxymethyl
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is methyl
  • R 2 is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC 5 -alkoxy, hydroxy-C 2 -C 4 -alkoxy or Ci-C2-alkoxy-C 2 -C 4 -alkoxy for the para position.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein R 1 is methyl;
  • R 2 is pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC 5 -alkoxy, hydroxy-C 2 -C 4 -alkoxy or Ci-C 2 -alkoxy-C2-C 4 -alkoxy for the para position.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is methyl
  • R 2 is a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F;.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is methyl
  • R 2 is phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 4-(3-hydroxypropoxy)-phenyl, 4- (2-hydroxyethoxy)-phenyl or 4-(2-methoxyethoxy)-phenyl.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is methyl
  • R 2 is 3-pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-pCs-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4- alkoxy for the para position.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is methyl
  • R 2 is 3-pyridyl.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is methyl;
  • R 2 is thiazolyl, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is methyl
  • R 2 is 2-thiazolyl which is unsubstituted or substituted by 1 to 2 substituents
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is methyl
  • R 2 is 2-thiazolyl
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is ethyl
  • R 2 is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, d-C 5 -alkoxy, hydroxy-C 2 -C 4 -alkoxy or C 1 -C 2 -alkoxy-C 2 -C 4 -alkoxy for the para position.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is ethyl
  • R 2 is pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC 5 -alkoxy, hydroxy-C 2 -C 4 -alkoxy or CrC 2 -alkoxy-C 2 -C 4 -alkoxy for the para position.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is ethyl
  • R 2 is a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is ethyl
  • R 2 is phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 4-(3-hydroxypropoxy)-phenyl, 4-
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is ethyl
  • R 2 is 3-pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-i-C 5 -alkoxy, hydroxy-C 2 -C 4 -alkoxy or C -C 2 -alkoxy-C 2 -C 4 - alkoxy for the para position.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is ethyl
  • R 2 is 3-pyridyl.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is ethyl
  • R 2 is thiazolyl, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is ethyl
  • R 2 is 2-thiazolyl which is unsubstituted or substituted by 1 to 2 substituents
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is ethyl
  • R 2 is 2-thiazolyl
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is hydroxymethyl
  • R 2 is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-pCs-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is hydroxymethyl
  • R 2 is pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-i-C 5 -alkoxy, hydroxy-C 2 -C 4 -alkoxy or C -C 2 -alkoxy-C 2 -C 4 -alkoxy for the para position.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is hydroxymethyl
  • R 2 is a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is hydroxymethyl
  • R 2 is phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 4-(3-hydroxypropoxy)-phenyl, 4- (2-hydroxyethoxy)-phenyl or 4-(2-methoxyethoxy)-phenyl.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is hydroxymethyl
  • R 2 is 3-pyridyl, which is unsubstituted or substituted in meta and/or para positions by
  • substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-pCs-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4- alkoxy for the para position.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is hydroxymethyl
  • R 2 is 3-pyridyl.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is hydroxymethyl
  • R 2 is thiazolyl, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is hydroxymethyl
  • R 2 is 2-thiazolyl which is unsubstituted or substituted by 1 to 2 substituents
  • the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
  • R 1 is hydroxymethyl
  • R 2 is 2-thiazolyl
  • the invention provides a compound and/or a pharmaceutically acceptable salt and/or a solvate therof, selected from
  • the invention provides a compound and/or a pharmaceutically acceptable salt and/or a solvate therof, selected from
  • an optical isomer or "a stereoisomer” refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom.
  • the term “chiral” refers to molecules which have the property of non-superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. "Enantiomers” are a pair of stereoisomers that are non- superimposable mirror images of each other.
  • a 1 :1 mixture of a pair of enantiomers is a "racemic" mixture.
  • the term is used to designate a racemic mixture where appropriate.
  • "Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
  • the absolute stereochemistry is specified according to the Cahn- Ingold- Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.
  • Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.
  • Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
  • the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms.
  • the present invention is meant to include all such possible isomers, including racemic mixtures, diasteriomeric mixtures and optically pure forms.
  • Optically active (f?)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
  • salt refers to an acid addition or base addition salt of a compound of the invention.
  • Salts include in particular “pharmaceutical acceptable salts”.
  • pharmaceutically acceptable salts refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable.
  • the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bi sulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/di
  • Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table.
  • the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
  • Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
  • a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
  • Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in "Remington's
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 3 C, 14 C, 15 N, 18 F 31 P, 32 P, 35 S, 36 CI, 125 l respectively.
  • the invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H and 14 C, or those into which nonradioactive isotopes, such as 2 H and 13 C are present.
  • isotopically labelled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 8 F or labeled compound may be particularly desirable for PET or SPECT studies.
  • Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
  • isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
  • a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • compositions in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 0, de- acetone, de-DMSO.
  • Compounds of the invention i.e. compounds of formula (I) that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co- crystals with suitable co-crystal formers.
  • These co-crystals may be prepared from compounds of formula (I) by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of formula (I) with the co-crystal former under crystallization conditions and isolating co- crystals thereby formed.
  • Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of formula (I).
  • the term "pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289- 1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • a therapeutically effective amount of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1 ) at least partially alleviate, inhibit, prevent and/or ameliorate a condition, or a disorder or a disease (i) mediated by class I PI3 kinase, or (ii) associated with class I PI3 kinase activity, or (iii) characterized by activity (normal or abnormal) of class I PI3 kinase; or (2) reduce or inhibit the activity of class I PI3 kinase.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of class I PI3 kinase.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1 ) at least partially alleviate, inhibit, prevent and/or ameliorate a condition, or a disorder or a disease (i) mediated by class I PI3 kinase and mTOR, or (ii) associated with class I PI3 kinase and mTOR activity, or (iii) characterized by activity (normal or abnormal) of class I PI3 kinase and mTOR; or (2) reduce or inhibit the activity of class I PI3 kinase and mTOR.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of class I PI3 kinase and mTOR.
  • the term "subject" refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
  • primates e.g., humans, male or female
  • the subject is a primate.
  • the subject is a human.
  • the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • “treat”, “treating” or “treatment” refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • treatment refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
  • “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
  • a subject is "in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
  • any asymmetric atom e.g., carbon or the like
  • any asymmetric atom can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or ⁇ R,S)- configuration.
  • each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 %
  • a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
  • Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
  • any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
  • a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-0, 0'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid.
  • Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
  • HPLC high pressure liquid chromatography
  • the compounds of the present invention can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
  • the compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms.
  • solvate refers to a molecular complex of a compound of the present invention
  • solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like.
  • solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like.
  • hydrate refers to the complex where the solvent molecule is water.
  • the compounds of the present invention including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.
  • Compounds of the present invention may be synthesized by synthetic routes that include processes analogous to those well-known in the chemical arts, particularly in light of the description contained herein.
  • the starting materials are generally available from commercial sources or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, volumes 1-19, Wiley, New York (1967-1999 ed.), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)).
  • reaction scheme depicted below provides potential routes for synthesizing the compounds of the present invention as well as key intermediates.
  • Examples section below For a more detailed description of the individual reaction steps, see the Examples section below.
  • Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the inventive compounds.
  • specific starting materials and reagents are depicted in the schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions.
  • many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.
  • Suitable hydroxyl protecting groups include trialkylsilyl ethers where one or two of the alkyl groups can be replaced by phenyl.
  • the need for such protection is readily determined by one skilled in the art. For a general description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.
  • the invention relates to a process for manufacturing a compound of formula (I) comprising steps a and b. In one embodiment, the invention relates to a process for manufacturing a compound of formula (I) (Method A) comprising step a followed by step b.
  • the compound of formula (I) is obtained via the step a) of coupling the compound of formula (A), wherein R 3 is as defined for a compound of formula (I) above
  • Step a) is carried out in the presence of a base such as NaH.
  • the reaction is carried out in the presence of an organic solvent such as DMF at temperatures from 0 to 80°C for 20 to 30 min.
  • the reaction can be carried out under customary Buchwald- Hartwig conditions using a ligand such as Xantphos, X-Phos or 2-di-t-butylphosphino-2'- (N,N-dimethylamino)biphenyl with a palladium catalyst such as Pd 2 (dba) 3 or
  • Pd 2 (dba) 3 -CHCI 3 or Pd(OAc) 2 preferably Pd 2 (dba) 3 with Xantphos, in the presence of a base such as preferably Cs 2 C0 3 or ferf-BuONa, in an organic solvent such as an ether, preferably dioxane or THF.
  • a base such as preferably Cs 2 C0 3 or ferf-BuONa
  • organic solvent such as an ether, preferably dioxane or THF.
  • the reaction is preferably stirred at a temperature of approximately 80-120°C.
  • the reaction is preferably carried out under an inert gas such as nitrogen or argon. Typical reaction conditions known in the field for Buchwald-Hartwig reactions may be applied to the present process.
  • Step b) is carried out in the presence of a catalyst, such as a Pd(0) catalyst, e.g.
  • reaction aids such as a base, e.g. an aqueous base, such as aqueous Na 2 C0 3 , optionally in the presence of one or more diluents, particularly polar solvents, e.g. DME.
  • a base e.g. an aqueous base, such as aqueous Na 2 C0 3
  • diluents particularly polar solvents, e.g. DME.
  • the reaction is stirred at a temperature of approximately 80-120°C.
  • the reaction may be carried out under an inert gas such as nitrogen or argon. Typical reaction conditions known in the field for Suzuki reactions may be applied to the present process.
  • the invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure material.
  • Compounds of the invention and intermediates can also be converted into each other according to methods generally known to those skilled in the art.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the present invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition can be formulated for particular routes of administration such as topical administration; enteral administration such as for example oral or rectal administration; and parenteral administration such as for example intravenous, intra- muscular or subcutaneous administration.
  • routes of administration such as topical administration; enteral administration such as for example oral or rectal administration; and parenteral administration such as for example intravenous, intra- muscular or subcutaneous administration.
  • the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions).
  • the pharmaceutical compositions can be prepared according to methods known in the art.
  • compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifers and buffers, etc.
  • suitable compositions for topical application include aqueous solutions, suspensions, ointments, creams, gels, powders, oils or sprayable
  • formulations e.g., for delivery by aerosol or the like.
  • topical delivery systems will in particular be appropriate for dermal application, e.g., for use in creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art.
  • Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives etc. ,
  • a topical application may also pertain to an inhalation or to an intranasal application e.g., to the respiratory system. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
  • a dry powder either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids
  • application preferably refers to topical application such as epicutaneous application in a suitable composition comprising a compound of the present invention, or a pharmaceutically acceptable salt thereof, and a
  • compositions for epicutaneous application may comprise all pharmaceutical forms normally utilized for this route of administration and are well-known in the art including solutions, gels, lotions, suspensions, creams, powders, oils, ointments, foams, mousses, emulsions, microemulsions, milks, serums, aerosols, sprays, dispersions, microcapsules, vesicles and microparticles thereof. These compositions are formulated according to conventional techniques.
  • the term "dermatologically acceptable carrier” is a carrier which is suitable for topical application to the keratinous tissue, has good aesthetic properties, is compatible with the active agents of the present invention and any other components, and will not cause any untoward safety or toxicity concerns.
  • the dermatologically acceptable carrier can be in a wide variety of forms.
  • emulsion carriers including, but not limited to, oil-in-water, water-in-oil, water-in-oil-in- water, and oil-in-water-in-silicon emulsions, are useful herein.
  • a given component will distribute primarily into either the water or oil/silicon phase, depending on the water solubility/dispersibility of the component in the composition.
  • the composition suitable for epicutaneous application can contain various known additives such as excipients, binders, lubricants, and disintegrants.
  • oily materials such as various fats, oils, waxes, hydrocarbons, fatty acids, higher alcohols, ester oils, metallic soaps, animal or vegetable extracts, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, other components such as vitamins, amino acids, surfactants, colorants, dyes, pigments, fragrances, odor absorbers, antiseptics, preservatives, bactericides, humectants, thickeners, solvents, fillers, antioxidants, sequestering agents, sunscreens, and the like and combinations thereof, as would be known to those skilled in the art, as long as these are compatible with the active ingredient.
  • oily materials such as various fats, oils, waxes, hydrocarbons, fatty acids, higher alcohols, ester oils, metallic soaps, animal or vegetable extracts, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, other components such as vitamins, amino acids, surfactants, colorants, dyes, pigments, fragrances,
  • suitable oils includes mineral oils, plant oils such as peanut oil, sesame oil, soybean oil, safflower oil, sunflower oil, animal oils such as lanolin or perhydrosqualene, synthetic oils such as purcellin oil, silicone oils such as cyclomethicome among others.
  • mineral oils such as peanut oil, sesame oil, soybean oil, safflower oil, sunflower oil, animal oils such as lanolin or perhydrosqualene, synthetic oils such as purcellin oil, silicone oils such as cyclomethicome among others.
  • Fatty alcohols, fatty acids such as stearic acid and waxes such as paraffin wax, carnauba wax or beeswax may also be used as fats.
  • composition may also contain emulsifying agents, solvents, hydrophilic gelling agents, lipophilic gelling agents, fatty acid metal salts, hydrophilic acting agents or lipophilic active agents.
  • the compounds of formula (I) in free form or in salt form exhibit valuable pharmacological properties, e.g. PI3 kinase modulating properties such as class I PI3 kinase (class I
  • PI3K's PI3K's modulating properties or PI3K's modulating properties in conjunction with mTOR modulating properties, e.g. as indicated in in vitro and in vivo tests as provided in the Experimental section, and are therefore indicated for therapy or for use as research chemicals, e.g. as tool compounds.
  • the compounds of formula (I) in free form or in salt form are useful in the treatment of class I PI3 kinase dependent diseases, especially diseases depending on class I PI3K a and ⁇ -isoforms, as well as diseases depending on class I PI3 kinases, especially diseases depending on class I PI3K a and ⁇ -isoforms, in conjunction with mTOR.
  • Compounds that inhibit the activity of class I PI3K a and ⁇ -isoforms are considered to be of benefit because such compounds are considered to have the ability to avoid adaption mechanisms due to pathway rewiring through the other isoforms, compared to compounds with unique specificity, e.g. specificity for one member of the class I PI3K family.
  • equipotent it is meant that the compounds inhibit several isoforms to a comparable extent, e.g. as measured in an enzyme or cellular assay described herein.
  • the compounds of formula (I) show sufficient photostability in order to ensure and maximize activity of the compounds of formula (I) when administered epicutaneously to minimize potential irritation and side effects due to degradation products generated. Compounds with superior photostability will simplify technical development and supply due to minimized risks of photodegradation.
  • the compounds of formula (I) show good potency in cellular assays using human cell lines derived from cutaneous squamous cell carcinoma. Preferred compounds should demonstrate the ability to penetrate well into skin.
  • Compounds of the invention may be useful in the treatment of an indication selected from but not limited to non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma; their pre-malignant stages such as actinic keratosis, solar keratosis and chronically sun damaged skin; and other hyperproliferative skin disorders caused by dysregulation of skin fibroblasts such as skin fibrosis, scleroderma, hypertrophic scars or keloids.
  • the compounds of the invention may be particularly useful in the treatment of an indication selected from but not limited to non-melanoma skin cancers.
  • the compound of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agent(s).
  • the invention provides a product comprising a compound of formula (I) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy.
  • the therapy is the treatment of a disease or condition dependent on PI3 kinases.
  • Products provided as a combined preparation include a composition comprising the compound of formula (I) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of formula (I) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • the invention provides a pharmaceutical composition comprising a compound of formula (I) and another therapeutic agent(s).
  • a pharmaceutical composition comprising a compound of formula (I) and another therapeutic agent(s).
  • composition may comprise a pharmaceutically acceptable carrier, as described above.
  • the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I).
  • the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
  • the kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
  • the kit of the invention typically comprises directions for
  • the invention provides the use of a compound of formula (I) for treating a disease or condition mediated by PI3 kinases, wherein the medicament is prepared for administration with another therapeutic agent.
  • the invention also provides the use of another therapeutic agent for treating a disease or condition mediated by PI3 kinases, wherein the medicament is administered with a compound of formula (I).
  • the invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by class I PI3 kinase or mediated by class I PI3 kinase and mTOR, wherein the compound of formula (I) is prepared for administration with another therapeutic agent.
  • the invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by class I PI3 kinase or mediated by class I PI3 kinase and mTOR , wherein the other therapeutic agent is prepared for administration with a compound of formula (I).
  • the invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by class I
  • the invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by class I PI3 kinase or mediated by class I PI3 kinase and mTOR , wherein the other therapeutic agent is administered with a compound of formula (I).
  • the invention also provides the use of a compound of formula (I) for treating a disease or condition mediated by class I PI3 kinase or mediated by class I PI3 kinase and mTOR wherein the patient has previously (e.g. within 24 hours) been treated with another therapeutic agent.
  • the invention also provides the use of another therapeutic agent for treating a disease or condition mediated by class I PI3 kinase or mediated by class I PI3 kinase and mTOR , wherein the patient has previously (e.g. within 24 hours) been treated with a compound of formula (I).
  • the other therapeutic agent is selected from therapeutic agents suitable for the treatment of non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma; their pre-malignant stages such as actinic keratosis, solar keratosis and chronically sun damaged skin.
  • these other therapeutic agents can be selected from immunostimulatory compounds for example Toll-like receptor agonists such as imiquimod (Aldara®), or from anti-inflammatory agents such as diclofenac (Solaraze®).
  • the pharmaceutical composition or combination of the present invention can be in unit dosage of about 1 to about 1000 mg of active ingredient(s) for a subject of about 50 to about 70 kg, or about 1 to about 500 mg or about 1 to about 250 mg or about 1 to about 150 mg or about 0.5 to about 100 mg, or about 1 to about 50 mg of active ingredients.
  • Unit dosage can also be of about 50 to about 1000 mg of active ingredient(s) for a subject of about 50 to about 70 kg, or about 50 to about 500 mg or about 50 to about 250 mg or about 50 to about 150 mg or about 50 to about 100 mg of active ingredients.
  • the dosage may depend upon the particular dosage form used for delivering the active ingredient(s).
  • the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated.
  • the dosage can also depend on the bioavailability of the active ingredient in the species being treated.
  • a physician, pharmacist, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
  • the above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys, pigs, mini-pigs or isolated organs, tissues and preparations thereof.
  • the compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions prepared from e.g. 10 mM DMSO stock solution, and in vivo either enterally, parenterally, advantageously intravenously or topically, e.g., as a suspension, in aqueous solution or other solutions, such as e.g. in propylene glycol based solution.
  • the dosage in vitro may range between about 10 "3 molar and about 10 "9 molar concentrations.
  • a therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1 to about 500 mg/kg, or between about 1 to about 100 mg/kg.
  • starting materials are generally available from commercial sources such as Aldrich Chemicals Co. (Milwaukee, Wis.), Lancaster Synthesis, Inc. (Windham, N.H.), Acros Organics (Fairlawn, N.J.), Maybridge Chemical Company, Ltd. (Cornwall, England), Tyger Scientific (Princeton, N.J.), Chem-lmpex International, Inc. (Wood Dale, IL), and AstraZeneca Pharmaceuticals (London, England).
  • boronic ester intermediate used in the preparation of compounds of the present invention is either commercially available or may be prepared as described in the literature, or in an analogous manner, or can be prepared as described hereafter, or in an analogous manner.
  • dichloromethane (30 mL) was added dropwise at -30 °C under argon 2- (trimethylsilyl)thiazole (939 ⁇ , 5.97 mmol) over a period of 10 min. Then, the reaction mixture was stirred at -30°C for 20 minutes, allowed to warm to room temperature and stirred at room temperature for 2 hours. The reaction mixture was then concentrated at 30 °C and dissolved in THF (30 mL). TBAF (1 M in THF) (5.97 mL, 5.97 mmol) was added at 0 °C under argon and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated, and the residue was extracted with EtOAc.
  • Boc-L-alanal (9.99 g, 57.7 mmol) was dissolved in 200 mL of CH 2 CI 2 .
  • 2-(trimethylsilyl)- thiazole (9.90 g, 62.9 mmol) dissolved in 70 mL of CH 2 CI 2 was added to the reaction mixture at -20 °C under argon. After 21 hours at -20 °C, the reaction mixture was concentrated. The residue was then dissolved in 180 mL of THF, when TBAF (1 M in THF, 63.4 mL, 63.4 mmol) was added, and the reaction mixture was stirred for 4 hours at room temperature. The reaction mixture was then concentrated.
  • dimethoxyethane was added under argon 5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)-4-(trifluoromethyl)pyrimidin-2-amine (1 .08 g, 3.75 mmol), PdCI 2 (dppf)-CH 2 CI 2 (214 mg, 262 ⁇ ), and 2 M aqueous sodium carbonate (5.11 mL, 10.2 mmol).
  • the reaction mixture was stirred at 80 °C for 30 minutes.
  • the reaction mixture was then cooled to RT and diluted with 80 mL of EtOAc, the organic solvents were washed with aqueous NH 4 CI and brine, dried over MgS0 4 , filtered, and concentrated.
  • Examples 4 to 14 in Table 1 below can be made using procedures analogous to those described in examples 1-3, using the appropriate boronic ester intermediate and oxazolidinone.
  • the activity of a compound according to the present invention can be assessed by the following in vitro & in vivo methods
  • Test compounds were dissolved in DMSO (10 mM) and transferred into 1.4 mL flat bottom or V-shaped Matrix tubes carrying a unique 2D matrix chip by individual Novartis compound hubs. The numbers of these chips were distinctively linked to Novartis Pharma Numbers. The stock solutions were stored at -20°C if not used immediately. For the test procedure the vials were defrosted and identified by a scanner whereby a working sheet was generated that guided the subsequent working steps.
  • Pre-dilution plates 96 polypropylene well plates were used as pre-dilution plates. A total of 4 pre-dilution plates were prepared including 10 test compounds each on the plate positions A1-A10, one standard compound at A1 1 and one DMSO control at A12. The pattern of the dilution steps is summarized in Table 1. Programs have been written to run these pipetting steps on the HamiltonSTAR robots.
  • Assay plates Identical "assay plates” were then prepared by pipetting 50nl_ each of compound dilutions of the "master plates” into 384-well “assay plates”. The compounds were mixed with 4.5 ⁇ _ of assays components plus 4.5 ⁇ _ enzyme corresponding to a 1 :181 dilution enabling the final concentration of 10, 3.0, 1.0, 0.3, 0.1 , 0.03, 0.01 and 0.003 ⁇ , respectively. The preparation of the "master plates” was handled by the Matrix PlateMate Plus robot and replication of "assay plates" by the HummingBird robot.
  • Catalytically active human ⁇ 3 ⁇ , ⁇ 3 ⁇ , PI3K5, and mTOR were cloned, expressed and purtified as described (Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, de Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C (2008), Mol Cancer Ther.
  • the luminescence-based ATP detection reagent KinaseGlo was obtained from
  • Luminescence is a well established readout to determine ATP concentrations and can thus be used to follow the activity of many kinases regardless of their substrate.
  • the Kinase Glo Luminescent Kinase Assay (Promega, Madison/WI, USA) is a homogeneous HTS method of measuring kinase activity by quantifying the amount of ATP remaining in solution following a kinase reaction.
  • NBS Non Binding Styrene
  • 5 ⁇ _ of a mix of PI/OG with the PI3Ka and Pi3Kb subtypes were added.
  • Kinase reactions were started by addition of 5 ⁇ of ATP-mix containing in a final volume 10 ⁇ _ 10 mM TRIS-HCI pH 7.5, 3mM MgCI 2 , 50 mM NaCI, 0.05% CHAPS, 1 mM DTT and 1 ⁇ ATP, and occured at room temperature.
  • Reactions were stopped with 10 ⁇ of KinaseGlo and plates were read 10 mins later in a Synergy2 reader using an integration time of 0.1 seconds per well.
  • NVP- BGT226 (standard) was added to the assay plates to generate the 100% inhibition of the kinase reaction, and the 0% inhibition was given by the solvent vehicle (90% DMSO in water).
  • NVP-BGT226 was used as a reference compound and included in all assay plates in the form of 16 dilution points in duplicate.
  • IC 50 values of the percentage inhibition of each compound at 8 concentrations were derived by fitting a sigmoidal dose-response curve to a plot of assay readout over inhibitor concentration as described. All fits were performed with the program XLfit4 (ID Business Solutions, Guildford, UK).
  • TR-FRET AdaptaTM Universal Kinase Assay Kit was purchased from Invitrogen
  • the kit contains the following reagents: Adapta Eu-anti-ADP Antibody (Europium labeled anti-ADP antibody in HEPES buffered saline, Cat. No. PV5097), Alexa Fluor® 647-labeled ADP tracer (Alexa Fluor® 647-labeled ADP tracer in HEPES buffered saline, Cat. No. PV5098), proprietary TR- FRET dilution buffer pH 7.5 (Cat. No. PV3574).
  • Adapta Eu-anti-ADP Antibody Europium labeled anti-ADP antibody in HEPES buffered saline, Cat. No. PV5097
  • Alexa Fluor® 647-labeled ADP tracer Alexa Fluor® 647-labeled ADP tracer in HEPES buffered saline, Cat. No. PV5098
  • proprietary TR- FRET dilution buffer pH 7.5 Cat. No. PV3574
  • PIK3CD substrate Phosphatidylinositol was obtained from Invitrogen (vesicules consisting of 2 mM PI in 50mM HEPES pH7.5; Cat. No. PV5371 ).
  • PIK3CG substrate Phosphatidylinositol-4,5-bisphosphate (PIP(4,5)2 was obtained from Invitrogen (PIP2:PS large unilamellar vesicules consisting of 1 mM PIP2: 19mM PS in 50mM HEPES pH7.5, 3mM MgCI2, 1 mM EGTA; Cat. No. PV5100).
  • TR-FRET Time-Resolved Fluorescence Resonance Energy Transfer
  • TR-FRET assays for protein kinases use a long-lifetime lanthanide Terbium or Europium chelates as the donor species which overcome interference from compound autofluorescence or light scatter from precipitated compounds, by introducing a delay after excitation by a flashlamp excitation source. Results are often expressed as a ratio of the intensities of the acceptor and donor fluorophores. The ratiometric nature of such a value corrects for differences in assay volumes between wells, as well as corrects for quenching effects due to colored compounds.
  • the AdaptaTM assay can be divided into two phases : a kinase reaction phase and an ADP detection phase.
  • kinase reaction phase all kinase reaction components are added to the well and the reaction is allowed to incubate for a set period of time specific for each kinase.
  • a detection solution of Eu-labeled anti-ADP antibody, Alexa Fluor® 647-labeled ADP tracer, and EDTA are added to the assay well.
  • ADP formed by the kinase reaction will displace the Alexa Fluor® 647-labeled ADP tracer from the antibody, resulting in a decrease in TR-FRET signal.
  • the amount of ADP formed by the kinase reaction is reduced, and the resulting intact antibody-tracer interaction maintains a high TR-FRET signal.
  • the donor Europium-anti-ADP antibody
  • the acceptor Alexa Fluor® 647-labeled ADP tracer
  • the emission from the Alexa Fluor® 647 can be monitored with a filter centered at 665 nm because it is located between the emission peaks of the donor, which is measured at 615/620 nm.
  • ADP antibody and the Alexa Fluor® 647-labeled ADP tracer in TR-FRET dilution buffer (proprietary to IVG). Plates are read 15 to 60 mins later in a Synergy2 reader using an integration time of 0.4 seconds and a delay of 0.05 seconds. Control for the 100% inhibition of the kinase reaction was performed by replacing the PI3K by the standard reaction buffer. The control for the 0% inhibition was given by the solvent vehicle of the compounds (90% DMSO in H 2 0). The standard compound NVP-BGT226 was used as a reference compound and included in all assay plates in the form of 16 dilution points in duplicate.
  • TR-FRET assays for protein kinases uses a long-lifetime lanthanide Terbium or
  • Binding Assays are based on the binding and displacement of an Alexa Fluor® 647- labeled, ATP-competitive kinase inhibitors to the kinase of interest. Invitrogen's "Kinase
  • Tracers have been developed to address a wide range of kinase targets and are based on ATP-competitive kinase inhibitors, making them suitable for detection of any compounds that bind to the ATP site or to an allosteric site altering the conformation of the ATP site.
  • Inhibitors that bind the ATP site include both Type I kinase inhibitors, which bind solely to the ATP site, and Type II inhibitors (e.g., Gleevec®/lmatinib, Sorafenib,
  • Type III inhibitors are compounds that do not compete with ATP are loosely referred to as allosteric inhibitors.
  • a study of 15 diverse Type III inhibitors demonstrated that all but one compound was detected in the binding assay with equivalent potency to activity assays. The sole exception was a substrate- competitive compound, and thus not a true allosteric inhibitor.
  • LanthaScreen® Eu 3+ Kinase Binding Assays can be read continuously, which facilitates evaluation of compounds with slow binding kinetics. Also, unlike most activity assays, binding assays can be performed using either active or non-activated kinase preparations, which enables characterization of compounds that bind preferentially to non-activated kinases, such as Gleevec®/imatinib and some allosteric inhibitors.
  • Alexa Fluor® 647 inhibitor can be monitored with a filter centered at 665 nm because it is located between the emission peaks of the donor, which is measured at 615/620 nm.
  • the binding of both, the Tracer-314 and Eu 3+ -anti-GST antibody, to the kinase results in a high degree of FRET from the Eu 3+ -donor fluorophore to the Alexa-Fluor® 647- acceptor fluorophore on the Tracer-314. Binding of an inhibitor to the kinase competes for binding with the tracer, resulting in a loss of FRET.
  • the standard reaction buffer for the LanthascreenTM kinase binding assay contained 50mM HEPES pH 7.5, 5mM MgCI2, 1 mM EGTA, 0.01 % Pluronic F-
  • Plates are read 60 mins later in a Synergy2 reader using an integration time of 0.2 microseconds and a delay of 0.1 microseconds.
  • the signal emitted at 665 nm from the acceptor (Alexa Fluor® 647-labeled Tracer-314) is divided by the signal emitted at 620 nm from the donor (Eu 3+ anti-GST antibody)
  • Control for the 0% inhibition was given by the solvent vehicle of the compounds (90% DMSO in H 2 0). Control for the relative 100% inhibition was performed by adding 10 ⁇ in the mix containing GST-mTOR and Europium anti-GST antibody. An additional control for the absolute 0% inhibition is given by Eu 3+ anti-GST antibody without GST-mTOR.
  • AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay, ALPHA, Perkin Elmer) is a non-radioactive bead-based proximity assay technology to study
  • the brand name SureFire denotes AlphaScreen assays that are adapted to quantify the phosphorylation of endogenous cellular proteins in cell lysates, by using matched antibody pairs, which consist of an anti-phospho-kinase and an anti-kinase antibody.
  • the assay allows characterization of kinase signaling in cells as well as measurement of kinase inhibitor effects.
  • the AlphaScreen technology provides several advantages over standard assay techniques such as ELISA, as it avoids time-consuming washing procedures and reduces plate handling.
  • Rat-1 cell lines stably overexpressing activated PI3K class I isoforms Rat-1 pBABEpuro Myr-HA-hp1 10 delta (Rat-1_PI3Kdelta) and Rat-1 pBABEpuro Myr-HA- hpH Oalpha (Rat-1_PI3Kalpha) and Rat-1 pBABEpuro Myr-HA-hp1 10 beta (Rat- 1_PI3beta) were prepared as described (Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, de Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C (2008), Mol Cancer Ther. 7:1851 -63 and Maira SM, Pecchi S, Brueggen J, Huh K, Schnell C, Fritsch
  • Dulbecco's modified Eagle's medium (DMEM) high glucose (Gibco Invitrogen, Basel,
  • the p-Akt(S473) SureFire assay measures the phosphorylation of endogenous cellular Akt 1/2 at Ser473 in cell lysates.
  • Rat-1 cells stably expressing myr-HA-tagged versions of the human PI3Kdelta, PI3Kalpha, or PI3Kbeta p110 catalytic subunit isoforms the assay was developed as a two-plate protocol in a 384-well format.
  • the cells were seeded at a density of 4000 (Rat-1_PI3Kdelta), 7500 (Rat-1_PI3Kalpha), or 6200 (Rat-1_PI3Kbeta) cells in 20 ul complete growth medium into cell culture treated 384-well plates and were grown at 37°C / 5 % C0 2 / 90 % humidity for 24 h. Shortly before compound transfer, the complete medium was removed, 30 ul assay buffer (DMEM high glucose, 1x MEM NEAA, 10 mM HEPES, 2 mM L-glutamine, 0.1 % (w/v) BSA) was added and 10 ul of the compound predilutions were transferred to the cells.
  • DMEM high glucose, 1x MEM NEAA, 10 mM HEPES, 2 mM L-glutamine, 0.1 % (w/v) BSA was added and 10 ul of the compound predilutions were transferred to the cells.
  • IC 50 values of the percentage inhibition of each compound at 8 concentrations were derived by fitting a sigmoidal dose-response curve to a plot of assay readout over inhibitor concentration as described. All fits were performed with the program XLfit4 (ID Business Solutions, Guildford, UK).
  • a cell based assay (384-well format) was developed for determination of compound effects on cellular mTOR activity in MEF (mouse embryo fibrobrasts) cells derived from mice lacking TSC1 (Tuberosclerosis Complexl ) a potent suppressor of mTOR activity. Due to lack of TSC1 , mTOR is constitutively activated resulting in permanent phoshorylation of Thr 389 of S6 kinase 1 (S6K1 ) which is one of the downstream targets of mTOR.
  • TSC1 -/- MEFs cells were cultured in DMEM high glucose medium supplemented with 10% FBS (Invitrogen), 2mM Glutamine and 1% (w/v) Penicillin/Streptomycin at 37°C, 5% C0 2 .
  • the SureFire kit for determination of P70S6kinase phosphorylation was purchased from Perkin Elmer (p70S6K p-T389, #TGR70S50K) and the assay was performed according to the instructions of the supplier and according to the generic method for SureFire assays. Shortly, 5 ⁇ _ cell lysate per well were transferred to 384-well white proxy-plates (for luminescent readout) and mixed with 7 ⁇ _ A and 5 ⁇ _ B (final volume: 12 ⁇ _). After 3 h incubation in the dark at RT luminescence was read with the Envision Reader (Perkin Elmer). Untreated cells were used as control (high control) and cells treated with 3 ⁇ BEZ235 were used as low control. The assay window between the signals obtained for the high and the low controls were defined as 100 % and compound effects were expressed as percent inhibition. IC50 values were calculated from the dose response curves by graphical extrapolation.
  • Samples investigated for light stability were treated in a light stability chamber (Atlas CPS+, Serial Number 0704013). Solutions of 1.0mg/ml in ethanol were prepared for each molecule and aliquots of 0.5mL were dispensed into suitable micro tubes. All measurements were done in duplicate and compared to a reference wrapped in aluminium foil during light exposure. Solutions were exposed to 19620kJ/m 2 over 13h.
  • the SCL-1 and SCC12B2 are human cutaneous squamous cell carcinoma (SCC) cell lines derived from naturally occurring, poorly differentiated SCCs.
  • SCC human cutaneous squamous cell carcinoma
  • the SCC12B2 cell line was established as described previously (Rheinwald & Beckett 1981 ) from the facial skin of a male transplant patient who received immunosuppressive therapy for 7 years.
  • the human SCC cell line Detroit562 was obtained from American Tissue Culture Collection (ATCC).
  • Detroit562 is referred to as Head&Neck squamous cell carcinomas (HNSCC) and was derived from a pharyngeal SCC tumor.
  • the Detroit562 cell line bears the activating mutation H1047R of the PIK3CA gene. This mutation is known as one of the "hotspot" mutations of p1 10a -chain rendering this kinase isoform constitutively active and stimulating the Akt/mTOR pathway independent of growth factor receptor activation.
  • DMEM Dulbecco modified Eagle's medium
  • FCS Gibco; #16000-044
  • sodium-pyruvat Gibco; #11360-039
  • 10mM HEPES Gibco; #91002-066
  • 50U/ml penicillin 50 ⁇ g/ml streptomycin mixture
  • Cells of SCC or keratinocyte lines were used for the proliferation assays when they had reached about 80% to 90% confluency. Cells were then harvested after trypsin-mediated dislodgement from culture flasks, washed in culture medium containing 10% FCS, counted in a hemocytometer and diluted complete culture medium with 5% FCS to obtain a cell density of 5x10 4 cells/ml. 100 ⁇ of this cell suspension (e.g. 5000 cells) were transferred into each well of a 96-well white walled tissue culture plate (Corning-Costar article #3917).
  • the BrdU reagent was diluted 1 :100 with complete culture medium to obtain a concentration of 100 ⁇ BrdU. From this solution, 20 ⁇ were added to each well and the cell culture was further incubated for 16 to 18 hours at 37°C at 5% C0 2 . The proliferation assay was stopped after 44 to 46 hours by complete removal of the culture medium and addition of 200 ⁇ fixing solution (provided with the ELISA kit) for 30 minutes at room temperature. All further incubations, washings and assay development procedures were performed exactly as described in the ELISA assay manual provided by the
  • Anti-proliferative potency of compounds measured in SCC cell lines The data obtained using these SCC and keratinocyte cell lines are shown in the following table. All values indicating the anti-proliferative potency represent the nanomolar IC50
  • the compound was applied as 0.5% solutions in propylene glycol mixed with either ethanol or oleylalcohol to pig skin mounted in static Franz-type diffusion cells. At the end of a 48 hours exposure time, drug concentrations were measured in the skin (after removal of stratum corneum) and in the receiver.
  • the receiver solution is a mixture of two volume parts of phosphate-buffered saline (PBS) and one volume part of fetal calf serum (FCS).
  • PBS phosphate-buffered saline
  • FCS fetal calf serum
  • Skin concentrations are given as mean ⁇ standard deviation of quadruplicate determinations.
  • the compound of example 1 penetrates well into pig skin in vitro, while permeation rate through pig skin is low, indicating a low systemic exposure.
  • Pig skin is similar to human skin regarding barrier function and architecture.
  • the following table provides dermal concentrations of the compound of example 1 in pig dermis when applied epicutaneously in the identified formulations.
  • the data table provides the mean ⁇ standard error of the mean of 8 determinations (e.g. eight skin samples analyzed for each time point).
  • Tween®80 polyoxyethylenesorbitan monooleate
  • HPMC hydroxypropylmethylcellulose

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

Description

Oxazolidin-2-one-Pyrimidine Derivatives FIELD OF THE INVENTION
The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3 kinases.
BACKGROUND OF THE INVENTION
The phosphatidylinositol-3-kinases superfamily comprises 4 different PI3K related lipid or protein kinases. Class I, II and III are lipid kinases that differ from their substrate specificities whereas class IV PI3K also called PI3-kinase-related protein kinase (PIKK) are protein kinases. Class I PI3Ks comprise a family of lipid kinases that catalyze the transfer of phosphate to the D-3' position of inositol lipids to produce phosphoinositol-3- phosphate (PIP), phosphoinositol-3,4-diphosphate (PIP2) and phosphoinositol-3,4,5- triphosphate (PIP3) that, in turn, act as second messengers in signaling cascades by docking proteins containing pleckstrin-homology, FYVE, Phox and other phospholipid- binding domains into a variety of signaling complexes often at the plasma membrane
(Vanhaesebroeck et al., Annu. Rev. Biochem 70:535 (2001 )). Aberrant regulation of PI3K, which often increases survival and proliferation through activation of AKT kinase is one of the most prevalent events in human cancer and has been shown to occur at multiple levels (Liu et al., Nat Rev Drug Discov 8:627-644 (2009)). For instance, somatic missense mutations in PIK3CA that activate downstream signaling pathways have been described at significant frequencies in a wide diversity of human cancers (Huang et al., Science 318: 1744-1748 (2007), Zhao & Vogt, Oncogene 27:5486-5496 (2008)). The tumor suppressor gene PTEN, which dephosphorylates phosphoinositides at the 3' position of the inositol ring and in so doing antagonizes PI3K activity, is functionally mutated or deleted in a variety of tumors (Keniry & Parsons, Oncogene 27:5477-5485 (2008)). Some studies indicate that the failure to express PTEN can mediate a shift of signaling dependence from the PI3Ka to the β-isoform (Wee et al, Pore Natl Acad Sci USA 105:13057-13062 (2008)). Therefore, inhibition of both class I PI3K a and β-isoforms can be particularly advantageous in cancers that are deficient in PTEN phosphatase.
Published international patent application WO2007/084786 describes substituted pyrimidine molecules that inhibit PI3K. It is well established that activation of Akt results in the stimulation of the kinase activity of the mammalian target of rapamycin (mTOR). mTOR is a protein kinase and a member of the class IV PI3K. In mammalian cells, mTOR is found in two distinct protein complexes called mTORCI and mTORC2. Activation of mTORCI is dependent on active PI3K and Akt kinases. Regulation of mTORC2 activation is more complex. mTORC2 is responsible for enhancement of Akt kinase activity via phosphorylation of serine residue 473
(Sarbassov et al., Science 307:1098-1 101 (2005), Bayascas & Alessi, Mol Cell 18(2):143- 145 (2005)). Catalytic inhibition of class I PI3K isoforms concomitant with inhibition of mTOR might therefore represent an additional benefit, potentially introducing a stronger effect on the PI3K-Akt pathway.
Cutaneous squamous cell carcinoma (SCC) represents the second most frequent human skin cancer, commonly preceded by actinic keratosis (AK). The pathogenesis of AK and cutaneous SCC has been associated with chronic UV exposure as one major risk factor (Salasche, J Am Acad Dermatol 42: 4-7 (2000)). An enhanced activity of PI3K/Akt/mTOR pathway has been suggested in a previous study (Chen et al., Br J Dermatol; 160 (2):442- 445 (2009)). It has been shown that prolonged UV-B irradiation causes a downregulation of PTEN expression at the mRNA and protein level in human keratinocytes in vitro, promoting their survival and growth (Ming et al., Oncogene; 29(4):492-502 (2010)). Based on recent literature, there is a causal link between chronic UV-irradiation and
downregulation of PTEN (Darido et al., Cancer Cell; 20(5):635-648 (201 1 )). Therefore, cutaneous SCC and AK and chronically sun-damaged skin can all be associated with a deficiency of PTEN expression leading to an activation of the PI3K/Akt/mTOR signaling pathway.
SUMMARY OF THE INVENTION
The invention relates to oxazolidin-2-one substituted pyrimidine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof,
Figure imgf000004_0001
(I)
wherein,
R1 is methyl, ethyl or hydroxymethyl;
R2 is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC5-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position,
or
pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-rC5-alkoxy, hydroxy-C2-C4-alkoxy or C1-C2-alkoxy-C2-C4-alkoxy for the para position,
or
a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F;
and
R3 is H or methyl.
Unless specified otherwise, the term "compounds of the present invention" refers to compounds of formula (I) and subformulae thereof, salts of the compound, hydrates or solvates of the compounds and/or salts, as well as all stereoisomers (including diastereoisomers and enantiomers), tautomers and isotopically labeled compounds (including deuterium substitutions). Compounds of the present invention further comprise polymorphs of compounds of formula (I) (or subformulae thereof) and salts thereof. Where compounds of formula (I) are mentioned, this is meant to include also the tautomers and N-oxides of the compounds of formula (I). The compounds of formula (I) are considered suitable to be used in the treatment of diseases dependent on PI3 kinases. The compounds of formula (I) are considered suitable, for example, to be used in the treatment of diseases dependent on class I PI3 kinase or dependent on class I PI3 kinase and mTOR.
DETAILED DESCRIPTION OF THE I NVENTION
The invention may be more fully appreciated by reference to the following description, including the following glossary of terms and the concluding examples. As used herein, the terms "including", "containing" and "comprising" are used herein in their open, non- limiting sense.
The general terms used hereinbefore and hereinafter preferably have within the context of this disclosure the following meanings, unless otherwise indicated: As used herein, the term "alkoxy" refers to a fully saturated branched, including single or multiple branching, or unbranched hydrocarbon moiety attached to the rest of the molecule via an -O- linking group. Unless otherwise provided, alkoxy refers to moieties having 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 7 carbon atoms, or 1 to 4 carbon atoms. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n- propoxy, /'so-propoxy, n-butyoxy, sec-butoxy, so-butoxy, iert-butoxy, n-pentoxy, isopentoxy, neopentyl, n-hexyloxy.
As used herein, the term "pyridyl" refers to 2-pyridyl, 3-pyridyl or 4-pyridyl. Substituents in meta or para position are attached to a carbon atom of the pyridyl. A representative example is 3-pyridyl.
As used herein, for substituents on 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S are attached to a carbon atom of the heteroaryl. Examples of 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S include, but are not limited to thiazolyl, oxazolyl, 1 ,2,4-oxadiazolyl, 1 ,3,4- oxadiazolyl and 1 ,3,4-thiadiazolyl. A representative example is thiazolyl.
Various embodiments of the invention are described herein. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention. In one embodiment, the invention provides a compound of the formula (I) and/or a pharmaceutically acceptable salt and/or a solvate thereof, selected from a compound of the formula (la)
Figure imgf000006_0001
(la)
wherein R1 and R2 are as defined for a compound of formula (I) above.
In one embodiment, the invention provides a compound of the formula (I) and/or a pharmaceutically acceptable salt and/or a solvate thereof, selected from a compound of the formula (lb)
Figure imgf000006_0002
(lb)
wherein R1 and R2 are as defined for a compound of formula (I) above.
In one embodiment, the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R2 is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-pCs-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position.
In another embodiment, the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R2 is pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-pCs-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position.
In another embodiment, the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R2 is a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
In one embodiment, the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R2 is phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 4-(3-hydroxypropoxy)-phenyl, 4- (2-hydroxyethoxy)-phenyl or 4-(2-methoxyethoxy)-phenyl.
In another embodiment, the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R2 is 3-pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC5-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4- alkoxy for the para position.
In another embodiment, the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R2 is 3-pyridyl.
In another embodiment, the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein R2 is thiazolyl, which is unsubstituted or substituted by 1 to 2 substituents
independently selected from D or F.
In another embodiment, the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R2 is 2-thiazolyl which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
In another embodiment, the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R2 is 2-thiazolyl.
In one embodiment, the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is methyl.
In another embodiment, the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is ethyl.
In another embodiment, the invention provides a compound of the formulae (I), (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is hydroxymethyl.
In one embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is methyl;
R2 is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC5-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein R1 is methyl;
R2 is pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC5-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is methyl;
R2 is a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F;.
In one embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is methyl;
R2 is phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 4-(3-hydroxypropoxy)-phenyl, 4- (2-hydroxyethoxy)-phenyl or 4-(2-methoxyethoxy)-phenyl. In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is methyl;
R2 is 3-pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-pCs-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4- alkoxy for the para position.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is methyl;
R2 is 3-pyridyl.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is methyl; R2 is thiazolyl, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is methyl;
R2 is 2-thiazolyl which is unsubstituted or substituted by 1 to 2 substituents
independently selected from D or F;. In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is methyl;
R2 is 2-thiazolyl.
In one embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is ethyl;
R2 is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, d-C5-alkoxy, hydroxy-C2-C4-alkoxy or C1-C2-alkoxy-C2-C4-alkoxy for the para position.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is ethyl;
R2 is pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC5-alkoxy, hydroxy-C2-C4-alkoxy or CrC2-alkoxy-C2-C4-alkoxy for the para position.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is ethyl;
R2 is a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F. In one embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is ethyl;
R2 is phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 4-(3-hydroxypropoxy)-phenyl, 4-
(2-hydroxyethoxy)-phenyl or 4-(2-methoxyethoxy)-phenyl.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is ethyl;
R2 is 3-pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-i-C5-alkoxy, hydroxy-C2-C4-alkoxy or C -C2-alkoxy-C2-C4- alkoxy for the para position.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is ethyl;
R2 is 3-pyridyl.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is ethyl;
R2 is thiazolyl, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is ethyl;
R2 is 2-thiazolyl which is unsubstituted or substituted by 1 to 2 substituents
independently selected from D or F.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is ethyl; R2 is 2-thiazolyl.
In one embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is hydroxymethyl;
R2 is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-pCs-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is hydroxymethyl;
R2 is pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-i-C5-alkoxy, hydroxy-C2-C4-alkoxy or C -C2-alkoxy-C2-C4-alkoxy for the para position.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is hydroxymethyl;
R2 is a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
In one embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is hydroxymethyl;
R2 is phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 4-(3-hydroxypropoxy)-phenyl, 4- (2-hydroxyethoxy)-phenyl or 4-(2-methoxyethoxy)-phenyl.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is hydroxymethyl;
R2 is 3-pyridyl, which is unsubstituted or substituted in meta and/or para positions by
1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-pCs-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4- alkoxy for the para position.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is hydroxymethyl;
R2 is 3-pyridyl.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is hydroxymethyl;
R2 is thiazolyl, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is hydroxymethyl;
R2 is 2-thiazolyl which is unsubstituted or substituted by 1 to 2 substituents
independently selected from D or F.
In another embodiment, the invention provides a compound of the formulae (la) or (lb) and/or a pharmaceutically acceptable salt and/or a solvate thereof, wherein
R1 is hydroxymethyl;
R2 is 2-thiazolyl.
In another embodiment, the invention provides a compound and/or a pharmaceutically acceptable salt and/or a solvate therof, selected from
3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-methyl-5-thiazol-
2- yl-oxazolidin-2-one,
3- (2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5-(4- methoxyphenyl)oxazolidin-2-one,
3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-(hydroxymethyl)-5- (4-methoxyphenyl)oxazolidin-2-one,
3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5- phenyloxazolidin-2-one, 3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-methyl-5- phenyloxazolidin-2-one,
3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5-(3- methoxyphenyl)oxazolidin-2-one,
3-(2'-amino-2-morpholino-4'-(tnfluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5-(th yl)oxazolidin-2-one,
3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-ethyl-5-pyri yl-oxazolidin-2-one,
3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-methyl-5-p 3-yl-oxazolidin-2-one,
3-(2'-amino-2-morpholin-4-yl-4^rifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-hydroxym 5-phenyl-oxazolidin-2-one,
3-(2'-amino-2-morpholin-4-yl-4' rifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-methyl-^
2- yl-oxazolidin-2-one,
3- (2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-(hydroxymet^ (4-(2-methoxyethoxy)phenyl)oxazolidin-2-one,
3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-5-(4-(2- hydroxyet oxy)phenyl)-4-(hydroxymethyl)oxazolidin-2-one or
3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-(hydro
(4-(3-hydroxypropoxy)phenyl)oxazolidin-2-one.
In another embodiment, the invention provides a compound and/or a pharmaceutically acceptable salt and/or a solvate therof, selected from
(4S,5 )-3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-methyl- 5-thiazol-2-yl-oxazolidin-2-one,
(4S 5S*)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5- (4-methoxyphenyl)oxazolidin-2-one,
(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-(hydroxy- methyl)-5-(4-methoxyphenyl)oxazolidin-2-one,
(4S*,5R*)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4:5'-bipyrimidin]-6-yl)-4-ethyl-5- phenyloxazolidin-2-one,
(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-methyl-5- phenyloxazolidin-2-one,
(4R*,5R*)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5- (3-methoxyphenyl)oxazolidin-2-one,
(4S,5R)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5- (thiazol-2-yl)oxazolidin-2-one, 3-(2'-amino-2-morpholin-4-yl-4'-trifluo^
yl-oxazolidin-2-one,
3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-me
3-yl-oxazolidin-2-one,
(4S,5S)-3-(2'-amino-2-morpholin-4-yl-4^rifluoromethyl-[4,5']bipyrimidin
hydroxymethyl-5-phenyl-oxazolidin-2-one,
(4S,5S)-3-(2'-amino-2-morpholin-4-yl-4'-tnfluoromethyl-[4,5']bipyrimidin
5-thiazol-2-yl-oxazolidin-2-one,
(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl^
(hydroxymethyl)-5-(4-(2-methoxyethoxy)phenyl)oxazolidin-2-one,
(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-^
hydroxyethoxy)phenyl)-4-(hydroxymethyl)oxazolidin-2-one or
(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl^
(hydroxymethyl)-5-(4-(3-hydroxypropoxy)phenyl)oxazolidin-2-one.
Specific embodiments are provided by the specific exemplified compounds described herein.
As used herein, the term "an optical isomer" or "a stereoisomer" refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom. The term "chiral" refers to molecules which have the property of non-superimposability on their mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. "Enantiomers" are a pair of stereoisomers that are non- superimposable mirror images of each other. A 1 :1 mixture of a pair of enantiomers is a "racemic" mixture. The term is used to designate a racemic mixture where appropriate. "Diastereoisomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn- Ingold- Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
Depending on the choice of the starting materials and procedures, the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms. The present invention is meant to include all such possible isomers, including racemic mixtures, diasteriomeric mixtures and optically pure forms. Optically active (f?)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
As used herein, the terms "salt" or "salts" refers to an acid addition or base addition salt of a compound of the invention. "Salts" include in particular "pharmaceutical acceptable salts". The term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bi sulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, subsalicylate, tartrate, tosylate and trifluoroacetate salts.
Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine. The pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in "Remington's
Pharmaceutical Sciences", 20th ed., Mack Publishing Company, Easton, Pa., (1985); and in "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and
Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
Unless indicated otherwise, any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, 11C, 3C, 14C, 15N, 18F 31P, 32P, 35S, 36CI, 125l respectively. The invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3H and 14C, or those into which nonradioactive isotopes, such as 2H and 13C are present. Such isotopically labelled compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 8F or labeled compound may be particularly desirable for PET or SPECT studies. Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
Furthermore, substitution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of the formula (I). The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D20, de- acetone, de-DMSO. Compounds of the invention, i.e. compounds of formula (I) that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co- crystals with suitable co-crystal formers. These co-crystals may be prepared from compounds of formula (I) by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of formula (I) with the co-crystal former under crystallization conditions and isolating co- crystals thereby formed. Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of formula (I).
As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289- 1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
The term "a therapeutically effective amount" of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1 ) at least partially alleviate, inhibit, prevent and/or ameliorate a condition, or a disorder or a disease (i) mediated by class I PI3 kinase, or (ii) associated with class I PI3 kinase activity, or (iii) characterized by activity (normal or abnormal) of class I PI3 kinase; or (2) reduce or inhibit the activity of class I PI3 kinase. In another non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of class I PI3 kinase.
In another embodiment, the term "a therapeutically effective amount" refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1 ) at least partially alleviate, inhibit, prevent and/or ameliorate a condition, or a disorder or a disease (i) mediated by class I PI3 kinase and mTOR, or (ii) associated with class I PI3 kinase and mTOR activity, or (iii) characterized by activity (normal or abnormal) of class I PI3 kinase and mTOR; or (2) reduce or inhibit the activity of class I PI3 kinase and mTOR. In another non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of class I PI3 kinase and mTOR.
As used herein, the term "subject" refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
As used herein, the term "inhibit", "inhibition" or "inhibiting" refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
As used herein, the term "treat", "treating" or "treatment" of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment "treat", "treating" or "treatment" refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, "treat", "treating" or
"treatment" refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, "treat", "treating" or "treatment" refers to preventing or delaying the onset or development or progression of the disease or disorder.
As used herein, a subject is "in need of" a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
As used herein, the term "a," "an," "the" and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as") provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or {R,S)- configuration. In certain embodiments, each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 %
enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the
(R)- or (S)- configuration. Substituents at atoms with unsaturated double bonds may, if possible, be present in c/'s- (Z)- or trans- (E)- form.
Accordingly, as used herein a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-0, 0'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
Furthermore, the compounds of the present invention, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. The compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms. The term "solvate" refers to a molecular complex of a compound of the present invention
(including pharmaceutically acceptable salts thereof) with one or more solvent molecules. Such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like. The term "hydrate" refers to the complex where the solvent molecule is water.
The compounds of the present invention, including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.
Compounds of the present invention may be synthesized by synthetic routes that include processes analogous to those well-known in the chemical arts, particularly in light of the description contained herein. The starting materials are generally available from commercial sources or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, volumes 1-19, Wiley, New York (1967-1999 ed.), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)).
For illustrative purposes, the reaction scheme depicted below provides potential routes for synthesizing the compounds of the present invention as well as key intermediates. For a more detailed description of the individual reaction steps, see the Examples section below. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the inventive compounds. Although specific starting materials and reagents are depicted in the schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions. In addition, many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.
In the preparation of compounds of the present invention, protection of remote functionality (e.g., hydroxyl groups) of intermediates may be necessary. The need for such protection will vary depending on the nature of the remote functionality and the conditions of the preparation methods. Suitable hydroxyl protecting groups include trialkylsilyl ethers where one or two of the alkyl groups can be replaced by phenyl. The need for such protection is readily determined by one skilled in the art. For a general description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.
Typically, the compounds of formula (I) can be prepared according to
the methods provided infra.
Scheme 1
Figure imgf000023_0001
(I)
In one embodiment, the invention relates to a process for manufacturing a compound of formula (I) comprising steps a and b. In one embodiment, the invention relates to a process for manufacturing a compound of formula (I) (Method A) comprising step a followed by step b. The compound of formula (I) is obtained via the step a) of coupling the compound of formula (A), wherein R3 is as defined for a compound of formula (I) above
Figure imgf000024_0001
with a compound of formula (B), wherein R1 and R2 are as defined for a compound of formula (I) above,
Figure imgf000024_0002
(B) to form a compound of formula (C) , wherein R1, R2 and R3 are as defined for a compound of formula (I) above,
Figure imgf000024_0003
followed by step b) of coupling the compound of formula (C) with a compound of formula (D), wherein -B(OR')2 represents a cyclic or acyclic boronic acid or boronic acid derivative, such as pinacolato-boron,
Figure imgf000025_0001
In cases where a protecting group is present a deprotection step is added to convert protected compound of formula (I) into compound of formula (I).
Step a) is carried out in the presence of a base such as NaH. The reaction is carried out in the presence of an organic solvent such as DMF at temperatures from 0 to 80°C for 20 to 30 min. Alternatively, the reaction can be carried out under customary Buchwald- Hartwig conditions using a ligand such as Xantphos, X-Phos or 2-di-t-butylphosphino-2'- (N,N-dimethylamino)biphenyl with a palladium catalyst such as Pd2(dba)3 or
Pd2(dba)3-CHCI3 or Pd(OAc)2, preferably Pd2(dba)3with Xantphos, in the presence of a base such as preferably Cs2C03 or ferf-BuONa, in an organic solvent such as an ether, preferably dioxane or THF. The reaction is preferably stirred at a temperature of approximately 80-120°C. The reaction is preferably carried out under an inert gas such as nitrogen or argon. Typical reaction conditions known in the field for Buchwald-Hartwig reactions may be applied to the present process.
Step b) is carried out in the presence of a catalyst, such as a Pd(0) catalyst, e.g.
PdCI2(dppf)-CH2CI2, optionally in the presence of one or more reaction aids, such as a base, e.g. an aqueous base, such as aqueous Na2C03, optionally in the presence of one or more diluents, particularly polar solvents, e.g. DME. The reaction is stirred at a temperature of approximately 80-120°C. The reaction may be carried out under an inert gas such as nitrogen or argon. Typical reaction conditions known in the field for Suzuki reactions may be applied to the present process.
Alternatively, compounds of formula (I) can also be synthesized by carrying out step b) followed by step a) (Method B).
The invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure material. Compounds of the invention and intermediates can also be converted into each other according to methods generally known to those skilled in the art.
In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The pharmaceutical composition can be formulated for particular routes of administration such as topical administration; enteral administration such as for example oral or rectal administration; and parenteral administration such as for example intravenous, intra- muscular or subcutaneous administration. In addition, the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions). The pharmaceutical compositions can be prepared according to methods known in the art. The
pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifers and buffers, etc. Suitable compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels, powders, oils or sprayable
formulations, e.g., for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, e.g., for use in creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives etc. ,
As used herein a topical application may also pertain to an inhalation or to an intranasal application e.g., to the respiratory system. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
In the context of the present invention, application preferably refers to topical application such as epicutaneous application in a suitable composition comprising a compound of the present invention, or a pharmaceutically acceptable salt thereof, and a
pharmaceutically dermatologically acceptable carrier. Suitable compositions for epicutaneous application may comprise all pharmaceutical forms normally utilized for this route of administration and are well-known in the art including solutions, gels, lotions, suspensions, creams, powders, oils, ointments, foams, mousses, emulsions, microemulsions, milks, serums, aerosols, sprays, dispersions, microcapsules, vesicles and microparticles thereof. These compositions are formulated according to conventional techniques.
As used herein, the term "dermatologically acceptable carrier", is a carrier which is suitable for topical application to the keratinous tissue, has good aesthetic properties, is compatible with the active agents of the present invention and any other components, and will not cause any untoward safety or toxicity concerns.
The dermatologically acceptable carrier can be in a wide variety of forms. For example, emulsion carriers, including, but not limited to, oil-in-water, water-in-oil, water-in-oil-in- water, and oil-in-water-in-silicon emulsions, are useful herein. As will be understood by the skilled artisan, a given component will distribute primarily into either the water or oil/silicon phase, depending on the water solubility/dispersibility of the component in the composition. The composition suitable for epicutaneous application, if desired, can contain various known additives such as excipients, binders, lubricants, and disintegrants. If desired, it can also contain oily materials such as various fats, oils, waxes, hydrocarbons, fatty acids, higher alcohols, ester oils, metallic soaps, animal or vegetable extracts, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, other components such as vitamins, amino acids, surfactants, colorants, dyes, pigments, fragrances, odor absorbers, antiseptics, preservatives, bactericides, humectants, thickeners, solvents, fillers, antioxidants, sequestering agents, sunscreens, and the like and combinations thereof, as would be known to those skilled in the art, as long as these are compatible with the active ingredient.
Examples of suitable oils includes mineral oils, plant oils such as peanut oil, sesame oil, soybean oil, safflower oil, sunflower oil, animal oils such as lanolin or perhydrosqualene, synthetic oils such as purcellin oil, silicone oils such as cyclomethicome among others. Fatty alcohols, fatty acids such as stearic acid and waxes such as paraffin wax, carnauba wax or beeswax may also be used as fats.
The composition may also contain emulsifying agents, solvents, hydrophilic gelling agents, lipophilic gelling agents, fatty acid metal salts, hydrophilic acting agents or lipophilic active agents.
The compounds of formula (I) in free form or in salt form, exhibit valuable pharmacological properties, e.g. PI3 kinase modulating properties such as class I PI3 kinase (class I
PI3K's) modulating properties or PI3K's modulating properties in conjunction with mTOR modulating properties, e.g. as indicated in in vitro and in vivo tests as provided in the Experimental section, and are therefore indicated for therapy or for use as research chemicals, e.g. as tool compounds.
The compounds of formula (I) in free form or in salt form, are useful in the treatment of class I PI3 kinase dependent diseases, especially diseases depending on class I PI3K a and β-isoforms, as well as diseases depending on class I PI3 kinases, especially diseases depending on class I PI3K a and β-isoforms, in conjunction with mTOR. Compounds that inhibit the activity of class I PI3K a and β-isoforms, in particular compounds that are substantially equipotent on class I PI3K a and β-isoforms and optionally as well inhibit the activity of mTOR, are considered to be of benefit because such compounds are considered to have the ability to avoid adaption mechanisms due to pathway rewiring through the other isoforms, compared to compounds with unique specificity, e.g. specificity for one member of the class I PI3K family. By "equipotent", it is meant that the compounds inhibit several isoforms to a comparable extent, e.g. as measured in an enzyme or cellular assay described herein.
Suitably, the compounds of formula (I) show sufficient photostability in order to ensure and maximize activity of the compounds of formula (I) when administered epicutaneously to minimize potential irritation and side effects due to degradation products generated. Compounds with superior photostability will simplify technical development and supply due to minimized risks of photodegradation. Suitably, the compounds of formula (I) show good potency in cellular assays using human cell lines derived from cutaneous squamous cell carcinoma. Preferred compounds should demonstrate the ability to penetrate well into skin.
Compounds of the invention may be useful in the treatment of an indication selected from but not limited to non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma; their pre-malignant stages such as actinic keratosis, solar keratosis and chronically sun damaged skin; and other hyperproliferative skin disorders caused by dysregulation of skin fibroblasts such as skin fibrosis, scleroderma, hypertrophic scars or keloids. The compounds of the invention may be particularly useful in the treatment of an indication selected from but not limited to non-melanoma skin cancers.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as") provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. In certain instances, it may be advantageous to administer the compound of the present invention in combination with at least one additional pharmaceutical (or therapeutic) agent (e.g., an anti-proliferative or anti-cancer agent or adjunct therapy typically used in chemotherapy). The compound of the present invention may be administered either simultaneously with, or before or after, one or more other therapeutic agent(s).
Alternatively, the compound of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agent(s).
In one embodiment, the invention provides a product comprising a compound of formula (I) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a disease or condition dependent on PI3 kinases. Products provided as a combined preparation include a composition comprising the compound of formula (I) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of formula (I) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
In one embodiment, the invention provides a pharmaceutical composition comprising a compound of formula (I) and another therapeutic agent(s). Optionally, the
pharmaceutical composition may comprise a pharmaceutically acceptable carrier, as described above.
In one embodiment, the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I). In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like. The kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit of the invention typically comprises directions for
administration.
Accordingly, the invention provides the use of a compound of formula (I) for treating a disease or condition mediated by PI3 kinases, wherein the medicament is prepared for administration with another therapeutic agent. The invention also provides the use of another therapeutic agent for treating a disease or condition mediated by PI3 kinases, wherein the medicament is administered with a compound of formula (I).
The invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by class I PI3 kinase or mediated by class I PI3 kinase and mTOR, wherein the compound of formula (I) is prepared for administration with another therapeutic agent. The invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by class I PI3 kinase or mediated by class I PI3 kinase and mTOR , wherein the other therapeutic agent is prepared for administration with a compound of formula (I). The invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by class I
PI3 kinase or mediated by class I PI3 kinase and mTOR , wherein the compound of formula (I) is administered with another therapeutic agent. The invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by class I PI3 kinase or mediated by class I PI3 kinase and mTOR , wherein the other therapeutic agent is administered with a compound of formula (I).
The invention also provides the use of a compound of formula (I) for treating a disease or condition mediated by class I PI3 kinase or mediated by class I PI3 kinase and mTOR wherein the patient has previously (e.g. within 24 hours) been treated with another therapeutic agent. The invention also provides the use of another therapeutic agent for treating a disease or condition mediated by class I PI3 kinase or mediated by class I PI3 kinase and mTOR , wherein the patient has previously (e.g. within 24 hours) been treated with a compound of formula (I).
In one embodiment, the other therapeutic agent is selected from therapeutic agents suitable for the treatment of non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma; their pre-malignant stages such as actinic keratosis, solar keratosis and chronically sun damaged skin. Suitably, these other therapeutic agents can be selected from immunostimulatory compounds for example Toll-like receptor agonists such as imiquimod (Aldara®), or from anti-inflammatory agents such as diclofenac (Solaraze®).
The pharmaceutical composition or combination of the present invention can be in unit dosage of about 1 to about 1000 mg of active ingredient(s) for a subject of about 50 to about 70 kg, or about 1 to about 500 mg or about 1 to about 250 mg or about 1 to about 150 mg or about 0.5 to about 100 mg, or about 1 to about 50 mg of active ingredients. Unit dosage can also be of about 50 to about 1000 mg of active ingredient(s) for a subject of about 50 to about 70 kg, or about 50 to about 500 mg or about 50 to about 250 mg or about 50 to about 150 mg or about 50 to about 100 mg of active ingredients. The dosage may depend upon the particular dosage form used for delivering the active ingredient(s). In general, the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. The dosage can also depend on the bioavailability of the active ingredient in the species being treated. A physician, pharmacist, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
The above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys, pigs, mini-pigs or isolated organs, tissues and preparations thereof. The compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions prepared from e.g. 10 mM DMSO stock solution, and in vivo either enterally, parenterally, advantageously intravenously or topically, e.g., as a suspension, in aqueous solution or other solutions, such as e.g. in propylene glycol based solution. The dosage in vitro may range between about 10"3 molar and about 10"9 molar concentrations. A therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1 to about 500 mg/kg, or between about 1 to about 100 mg/kg. EXAMPLES
The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees Celsius. If not mentioned otherwise, all evaporations are performed under reduced pressure, typically between about 15 mm Hg and 100 mm Hg (= 20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art.
All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesis the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, Methods of Organic Synthesis, Thieme, Volume 21 ). Further, the compounds of the present invention can be produced by organic synthesis methods known to one of ordinary skill in the art as shown in the following examples.
Unless specified otherwise, starting materials are generally available from commercial sources such as Aldrich Chemicals Co. (Milwaukee, Wis.), Lancaster Synthesis, Inc. (Windham, N.H.), Acros Organics (Fairlawn, N.J.), Maybridge Chemical Company, Ltd. (Cornwall, England), Tyger Scientific (Princeton, N.J.), Chem-lmpex International, Inc. (Wood Dale, IL), and AstraZeneca Pharmaceuticals (London, England).
Abbreviations
The abbreviations used in the following Examples have the corresponding meanings listed below.
AcOH acetic acid
aq aqueous
ax axial
Boc tert-butoxycarbonyl
Brine saturated (at RT) sodium chloride solution
br s broad singlet
CDCI3 deuterated chloroform
CHCI3-d deuterated chloroform
CH2CI2 dichloromethane
CH3CN acetonitrile cone. concentrated
CsF cesium fluoride
CuS04 copper sulfate
d doublet
DIPEA di-isopropylethyl amine
DME dimethoxyethane
DMF N,N-dimethylformamide
DMSO dimethylsulfoxide
DMSO-d6 deuterated dimethylsulfoxide
dppf 1 ,1 '-Bis(diphenylphosphino)ferrocene eq equatorial
ESI-MS electrospray mass spectrometry
Et20 diethyl ether
EtOH ethanol
EtOAc ethyl acetate
h hour(s)
Hyflo Hyflo Super Cel®
1HNMR proton nuclear magnetic resonance
KOAc potassium acetate
KHSO4 potassium hydrogensulfate
K2C03 potassium carbonate
LC-MS liquid chromatography-mass spectrometry
LDA lithiumdiisopropylamine
MeOH methanol
MgS04 magnesium sulfate
M molar
m multiplet
MS mass spectrometry
min minute(s)
ml_ milliliter(s)
m.p. melting point
MgS04 magnesium sulfate
MHz megahertz
N normal
NaHMDS sodium hexamethyldisilazane
NMR nuclear magnetic resonance
NEt3 triethylamine Na2S203 sodium thiosulfate
Na2S04 sodium sulfate
Pd2(dba)3 Tris(dibenzylideneacetone)dipalladium(0)
PdCI2(dppf) 1 ,1 '-Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride
PdCI2(dppf)-CH2CI2 1,r-Bis(diphenylphosphino)ferrocene-palladium(ll)dichloride dichloromethane complex
PPh3 triphenyl phosphine
Pd(PPh3)4 tetrakis(triphenylphosphine)palladium
Pd palladium
qt quintett
Raney-Ni Raney-nickel
RT room temperature
Rf TLC retention factor
Rt retention time
s singlet
Si02 silica gel
t triplet
TBAF tetrabutylammonium fluoride
TBDPSCI tert-butyldiphenylsilyl chloride
TBME tert-butylmethylether
TFA trifluoroacetic acid
THF tetrahydrofurane
TLC thin layer chromatography
tR time of retention
UV ultraviolet
UPLC ultra-performance liquid chromatography
General methods
1H-NMR measurements were performed on a Bruker Ultras ield 400 (400 MHz), Bruker Ultrashield™ 600 (600 MHz) or a 500 MHz DRX Bruker CryoProbe (500 MHz) spectrometer using or not trimethylsilane as an internal standard. Chemical shifts (d- values) are reported in ppm downfield from tetramethylsilane, coupling constants (J) are given in Hz, spectra splitting pattern are designated as singulet (s), doublet (d), doublet doublet (<±/), triplet (f), quadruplet (g), multiplet or more overlapping signals (m), broad signal {br). Solvents are given in parentheses. TLC were performed with precoated silica gel 60 F254 glass plates (Merck, Darmstadt, Germany) using the respective named solvent systems. Visualization was generally done by UV light (254 nm).
LC-MS:
LC-MS-Method 1
Column: Acquity HSS T3, 1 .δμπι, 2.1 x 50 mm;
Eluent: Water (+ 0.05% formic acid + 3.75 mM ammonium acetate) : acetonitrile (+ 0.04% formic acid), from 95:5 to 2:98 in 1 .4 min, hold 98% for 0.75 min;
Flow rate/Temperature: 1 .0 mL/min at 60°C
LC-MS-Method 2
Column: Acquity HSS T3, 1 .8μπι, 2.1 x 50 mm;
Eluent: Water (+ 0.05% formic acid + 3.75 mM ammonium acetate) : acetonitrile (+ 0.04% formic acid), from 98:2 to 2:98 in 1 .4 min, hold 98% for 0.75 min;
Flow rate/Temperature: 1 .2 mL/min at 50°C
UPLC 1
Column: Acquity UPLC HSS T3 C18, 1.7 μηι 2.1 x 50 mm, Flow: 1.0 mL / min. Gradient: 5% to 100% B in 1 .5 min, 100% B for 1 min, A = water + 0.1 % TFA, B = acetonitrile + 0.1 % TFA
Detection: 218 nm or 254 nm
Synthesis of boronic ester intermediate
The boronic ester intermediate used in the preparation of compounds of the present invention is either commercially available or may be prepared as described in the literature, or in an analogous manner, or can be prepared as described hereafter, or in an analogous manner.
Intermediate 1 : 5-(4,4,5,5-Tetramethyl-1 ,3,2-dioxaborolan-2-yl)-4- trifluoromethyl)pyrimidin-2-amine
Figure imgf000036_0001
a) 5-Bromo-4-trifluoromethyl-pyrimidin-2-ylamine
To a solution of 2-amino-4-trifluoromethylpyrimidine (25 g, 0.15 mol) in CH3CN (600 mL) was added in the dark a solution of N-bromosuccinimide (34.8 g, 195 mmol) in acetonitrile (200 mL) over a period of 2.5 h. The reaction mixture was stirred for 4.5 h at RT and then concentrated. The residue was dissolved in EtOAc and H20, the organic solvents were separated, washed with H20 and brine, dried over Na2S04, filtered and concentrated. The residue was purified by column chromatography using EtOAc in hexane from 10% to 40% to provide the title compound as a beige solid (31.2 g, 85 %). LC-MS: Rt 0.82 min; (LCMS method 2). b) 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)pyrimidin-2- amine
To a suspension of 5-Bromo-4-trifluoromethyl-pyrimidin-2-ylamine (16.2 g, 66.3 mmol), bis-pinacolatodiboron (18.5 g, 72.9 mmol) and KOAc (19.5 g, 199 mmol) in dioxane (300 mL) under argon was added PdCI2(dppf)-CH2CI2 adduct (2.44 g, 2.98 mmol) and the mixture was stirred for 4 h at 1 15 °C. The reaction mixture was cooled to 50 °C and treated with EtOAc. The resulting suspension was filtered over Hyflo and washed with EtOAc. The combined filtrate was concentrated. The residue was suspended in 2M NaOH, stirred at RT for 5 min and then Et20 and H20 were added. The binary mixture was filtered again through Hyflo and the phases were separated. The pH of the resulting aqueous layer was adjusted to 5-6 with 4M aqueous HCI, and the product was extracted with EtOAc. Combined extracts were washed with H20 and brine, dried over Na2S04, filtered and concentrated. The residue was triturated in Et20/hexane, filtered off and dried to afford the title compound as a light yellow solid (8.33 g, 42%). LC-MS: [M+H] 290.2; Rt 1.00 min; (LCMS method 2).
Synthesis of oxazolidinone intermediates
Intermediate 2: (4S*,5S*)-4-Ethyl-5-(4-methoxyphenyl)oxazolidin-2-one
Figure imgf000037_0001
a) (1 S*,2S*)-1 -(4-Methoxyphenyl)-2-nitrobutan-1 -ol
To a solution of LiAIH4 (2 M in THF) ( .84 ml_, 3.67 mmol) in dry THF (100 ml_), which had been stirred for 30 min at 0 °C, was added 1-nitropropane (16.3 ml_, 184 mmol) under argon. After 30 min, the 4-methoxybenzaldehyde (4.45 ml_, 36.7 mmol) was added in one portion. The mixture was stirred for 6 hours at 0°C and 18 hours at room temperature. The reaction mixture was quenched with HCI (1 M in H20) and extracted with CH2CI2. The organic layers were washed with brine, dried over MgSC , filtered and concentrated. The residue was purified by column chromatography using CH2CI2 in hexane from 0% to 100% to give the title compound (1.4 g, 34%). 1H NMR (600 MHz,
DMSO-de): 7.35 (d, 2H), 6.94 (d, 2H), 5.94 (d, 1 H), 4.80 (dd, 1 H), 4.68 - 4.52 (m, 1 H), 3.76 (s, 3H), 1.75-1.69 (m, 1 H), 1.25-1 .20 (m, 1 H), 0.74 (t, 3H). b) (1 S*,2S*)-2-Amino-1 -(4-methoxyphenyl)butan-1 -ol
A solution of (1 S*,2S*)-1 -(4-methoxyphenyl)-2-nitrobutan-1-ol (1.0 g, 4.44 mmol) in ethanol (20 mL) was purged with argon, and Pd/C (100 mg, 0.094 mmol) was added at room temperature. The sealed vessel was then purged and refilled with H2 and the reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was filtered over celite, washed with ethanol and concentrated. The residue was purified by column chromatography using CH2Cl2/MeOH/(NH4OH in H20) from 100:0:0 to 80:20:1 to yield the title compound as a white solid (450 mg, 51.4%). LC-MS: [M+H] 196.1 ; Rt 0.44 min; (LCMS method 2). c) (4S*,5S*)-4-Ethyl-5-(4-methoxyphenyl)oxazolidin-2-one
To a solution of (1S*,2S*)-2-amino-1 -(4-methoxyphenyl)butan-1-ol (440 mg, 2.25 mmol) in CH2CI2 (15 mL) was added under argon NEt3 (0.78 mL, 5.63 mmol) at 0 °C. Then diphosgene was added over a period of 5 minutes and the temperature was kept at 0 °C for 30 minutes. The reaction mixture was quenched with ice cold water and a 2 M aqueous solution of Na2C03, extracted with CH2CI2, dried over Na2S04, filtered and concentrated. The residue was triturated with TBME, filtered and dried to give intermediate 2 [(4S*,5S*)-4-ethyl-5-(4-methoxyphenyl)oxazolidin-2-one] as a white powder (220 mg, 44%). LC-MS: [M+H] 222.2; Rt 0.77 min; (LCMS method 2). 1H NMR (600 MHz, DMSO-de): 7.94 (br s, 1 H), 7.32 (d, 2H), 6.96 (d, 2H), 5.06 (d, 1 H), 3.74 (s, 3H), 3.51 (q, 1 H), 1.53 (qt, 2H), 0.85 (t, 3H).
Intermediate 3: (4S*,5S*)-4-Ethyl-5-(3-methoxyphenyl)oxazolidin-2-one
Figure imgf000038_0001
The title compound was prepared according to the procedure described for intermediate 2 [(4 *,5R*)-4-ethyl-5-(4-methoxyphenyl)oxazolidin-2-one] to yield intermediate 3 as a colorless oil. LC-MS: [M+H] 222.1 ; Rt 0.79 min; (LCMS method 2). 1H NMR (600 MHz, DMSO-d6): 7.98 (br s, 1 H), 7.35 - 7.29 (m, 1 H), 6.83 - 6.96 (m, 3H), 5.10 (d, 1 H), 3.72 - 3.78 (m, 3H), 3.36 - 3.29 (m, 1 H), 1 .49 - 1.63 (m, 2H), 0.88 (t, 3H).
Intermediate 4: (4S*,5R*)-4-Ethyl-5-phenyloxazolidin-2-one
Figure imgf000038_0002
The title compound was prepared according to the procedure described for intermediate 2 [(4R*,5R*)-4-ethyl-5-(4-methoxyphenyl)oxazolidin-2-one] to yield intermediate 4 as a white solid. LC-MS: [M+H] 192.1 ; Rt 0.77 min; (LCMS method 2)
Intermediate 5: (4S, 5S)-4-Methyl-5-phenyloxazolidin-2-one
Figure imgf000038_0003
To a solution of (1S,2S)-(+)-Norpseudoephedrine (2.00 g, 13.2 mmol) in CH2CI2 (60 mL) was added under argon Et3N (4.61 mL, 33.1 mmol) at 0 °C. Then, triphosgene ( .57 g, 5.29 mmol) dissolved in 20 mL of CH2CI2 was added slowly, and the temperature was allowed to warm from 0 °C to room temperature. The reaction mixture was stirred for 4 hours at room temperature. The reaction mixture was then quenched by addition of aqueous NH4CI. The organic layers were separated, dried over MgS04, filtered, and concentrated. The residue was purified by column chromatography using EtOAc in heptane from 0% to 100% in order to give the desired product (2.10 g, 89%). LC-MS: [M+H] 178.1 ; Rt 0.67 min; (LCMS method 2). 1 H NMR (400 MHz, DMSO-d6) 7.88 (br s, 1 H), 7.50-7.32 (m, 5H), 5.09 (d, 1 H), 3.78-3.62 (m, 1 H), 1.26 (d, 3H).
Intermediate 6: (4S,5R)-4-Ethyl-5-(thiazol-2-yl)oxazolidin
Figure imgf000039_0001
a) (S)-2-(((Benzyloxy)carbonyl)amino)butanoic acid
To a solution of (S)-2-aminobutanoic acid (1 1.2 g, 109 mmol) in THF (200 mL) and a 2 M aqueous sodium carbonate solution (65.2 ml, 130 mmol) was added dropwise at 0 °C benzyl carbonochloridate (17.06 mL, 1 19 mmol). After stirring at room temperature for 16 hours, the reaction mixture was extracted with H20/TBME, the aqueous layer was acidified with HCI (2M in H20) until pH = 2 and extracted with EtOAc. The organic layer was dried over Na2S04, filtered and the filtrate was concentrated to give the title compound (22.8 g, 77%) as a colorless oil. The product was used in the next step without further purification. LC-MS: [M-H] 236.2; Rt 0.76 min; (LCMS method 1 ). b) (S) -Methyl 2-(((benzyloxy)carbonyl)amino)butanoate
To a solution of (S)-2-(((benzyloxy)carbonyl)amino)butanoic acid (10.0 g, 42.1 mmol) in methanol (100 mL) and toluene (300 mL) was added dropwise at room temperature under argon trimethylsilyldiazomethane (23.2 mL, 46.4 mmol). After stirring at room temperature for 1 hour, the reaction mixture was concentrated and the residue was extracted with a solution of EtOAc and brine. The combined organic layers were dried over Na2S04, filtered and the filtrate was concentrated. The residue was purified by column chromatography (120 g Si02) using EtOAc in hexane from 0% to 30 % in order to give the title compound (5.2 g, 48%) as a colorless oil. LC-MS: [M+H] 252.1 ; Rt 0.93 min; (LCMS method 1 ). c) (S)-Benzyl (1-oxobutan-2-yl)carbamate
To a solution of (S)-methyl 2-(((benzyloxy)carbonyl)amino)butanoate (2.0 g, 7.96 mmol) in toluene (50 mL) was added dropwise at -78 °C under argon DIBAL-H (1 M in toluene) (15.9 mL, 15.9 mmol) over a period of 20 minutes and the reaction mixture was stirred at -78 °C for 1 hour. The reaction mixture was quenched at -78 °C with aqueous 1.5 M potassium sodium tartrate solution (20 mL), and was allowed to warm to room temperature. The reaction mixture was extracted with a solution of EtOAc and brine. The combined organic layers were dried over Na2S04, filtered and concentrated. The residue was purified by column chromatography (24 g Si02) using EtOAc in hexane from 0% to 30 % in order to give the title compound (1 .18 g, 64%) as a colorless oil. LC-MS: [M+H]
222.2; Rt 1.01 min; (LCMS method 1 ). 1H NMR (400 MHz, CHCI3-d): 9.61 (s, 1 H), 7.27 - 7.43 (m, 5H), 5.39 (br s, 1 H), 5.15 (m, 2H), 4.15 (q, 1 H), 1.96 - 2.1 1 (m, 1 H), 1.64 - 1.82 (m, 1 H), 1.01-0.79 (m, 3H). d) Benzyl ((1R,2S)-1 -hydroxy-1-(thiazol-2-yl)butan-2-yl)carbamate
To a solution of (S)-benzyl (1-oxobutan-2-yl)carbamate (1.1 g, 4.97 mmol) in
dichloromethane (30 mL) was added dropwise at -30 °C under argon 2- (trimethylsilyl)thiazole (939 μί, 5.97 mmol) over a period of 10 min. Then, the reaction mixture was stirred at -30°C for 20 minutes, allowed to warm to room temperature and stirred at room temperature for 2 hours. The reaction mixture was then concentrated at 30 °C and dissolved in THF (30 mL). TBAF (1 M in THF) (5.97 mL, 5.97 mmol) was added at 0 °C under argon and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated, and the residue was extracted with EtOAc. The combined organic layers were washed with aqueous sodium carbonate, water and brine, dried over Na2S04, filtered and the filtrate was concentrated. The residue was purified by column chromatography (24 g Si02) using EtOAc in hexane from 0% to 30% in order to give the title compound (1 .18 g, 64%) as a colorless oil. The residue was purified by column chromatography (24 g Si02) using MeOH in CH2CI2 hexane from 0% to 4 % in order to give the title compound (340 mg, 43%) as a colorless oil. LC-MS: [M+H] 307.5; Rt 0.86 min; (LCMS method 1 ). e) (1 R,2S)-2-Amino-1-(thiazol-2-yl)butan-1 -ol
To a solution of benzyl ((1 R,2S)-1-hydroxy-1 -(thiazol-2-yl)butan-2-yl)carbamate (330 mg, 1.077 mmol) in acetonitrile (25 mL) at 0°C under argon was added piperidine (0.213 mL, 2.154 mmol) and dropwise iodotrimethylsilane (293 μί, 2.15 mmol) over a period of 5 minutes. Then, the reaction mixture was allowed to warm to room temperature and was stirred at room temperature for 2 hours. To the reaction mixture was added at 0 °C sodium thiosulfate (500 mg), followed by water (0.5 ml_), and the reaction mixture was stirred vigorously at 0 °C for 15 minutes. Further 500 mg of sodium thiosulfate was added, and the mixture was diluted with EtOAc (50 ml_), dried over Na2S04, filtered and concentrated. The residue was triturated with EtOAc, filtered, and the filtrate was concentrated to give the title compound (250 mg, 67%) as a yellow oil. f) (4S,5R)-4-Ethyl-5-(thiazol-2-yl)oxazolidin-2-one
The title compound was prepared from (1 R,2S)-2-Amino-1 -(thiazol-2-yl)butan-1-ol according to the procedure described for intermediate 2 to yield intermediate 6 (410 mg, 95%) as a brown oil. This product was used in the next reaction step without further purification.
Intermediate 7: 4-Ethyl-5-pyridin-3-yl-oxazolidin-2-one
Figure imgf000041_0001
a) 2-Nitro-1 -pyridin-3-yl-butan-1 -ol
To a solution of LiAIH4 (2M in THF) (0.93 ml_, 1.87 mmol) in dry THF (80 mL) at 0 °C, was slowly added 1 -nitropropane (8.30 mL, 93 mmol) under argon. After 60 min, nicotinaldehyde (2.00 g, 18.7 mmol) was added in one portion. The mixture was stirred for 16 hours, while allowing the temperature to rise from 0 °C to room temperature. The reaction mixture was quenched by addition of 1 mL of 2M aqueous HCI, followed by addition of 4 grams of Na2S04. The resulting suspension was stirred for 15 minutes and then filtered. The filtrate was concentrated. The residue was purified by column chromatography (40 g Si02) using EtOAc in hexane from 0% to 100% in order to give the title compound as a white solid (2.6 g, 71 %) as a mixture of diastereoisomers A and B. LC-MS: [M+H] 197.1 ; Rt 0.52 min; (LCMS method 1 ). A) 1H NMR (400 MHz, CHCI3- d): 8.70-8.60 (m, 2H), 7.80-7.74 (m, 1 H), 7.42 - 7.32 (m, 1 H), 5.28 (dd, 1 H), 4.70-4.58 (m, 1 H), 2.97 (d, 1 H), 2.29-2.12 (m, 1 H), 1.65-1 .42 (m, 1 H), 0.99 (t, 3H). B) 1H NMR (400 MHz, CHCIa- /): 8.70-8.60 (m, 2H), 7.80-7.74 (m, 1 H), 7.42-7.32 (m, 1 H), 5.15 (dd, 1 H), 4.70-4.58 (m, 1 H), 2.81 (d, 1 H), 1.99-1.85 (m, 1 H), 1.65-1.42 (m, 1 H), 0.94 (t, 3H). b) 2-Amino-1 -pyridin-3-yl-butan-1 -ol A solution of 2-nitro-1 -pyridin-3-yl-butan-1 -ol (1 .0 g, 4.44 mmol) in ethanol (20 mL) was purged with argon, and 100 mg of Raney-Nickel was added at room temperature. The reaction mixture was three times evacuated and refilled with hydrogen. The reaction was stirred for 16 hours at room temperature. Raney-Nickel was then filtered over Hyflo, and the Hyflo washed with EtOH. The filtrate was then concentrated. The residue was purified by column chromatography (40 g of Si02) using MeOH in CH2CI2 from 0% to 100% in order to give the title compound as a yellow oil (180 mg, 21 %). LC-MS: [M+H] 167.1 ; Rt 0.21 min; (LCMS method 1 ). c) 4-Ethyl-5-pyridin-3-yl-oxazolidin-2-one
To a solution of 2-amino-1 -pyridin-3-yl-butan-1 -ol (150 mg, 0.90 mmol) in CH2CI2 (5 mL) was added under argon NEt3 (314 μί, 5.63 mmol) at 0 °C. Then, diphosgene was added over a period of 5 minutes and the temperature was allowed to warm from 0 °C to room temperature within 2 hours. The reaction mixture was quenched with ice cold water and a 2 M solution of Na2C03, extracted with CH2CI2, dried over MgS04, filtered and concentrated. The residue was purified by column chromatography using EtOAc in heptane from 0% to 100 % in order to give the title compound (100 mg, 58%) as a mixture of diastereoisomers A and B. LC-MS: [M+H] 193.1 ; Rt 0.43 min; (LCMS method 1 ). A) 1H NMR (400 MHz, CHC\3-d): 8.70-8.62 (m, 1 H), 8.60-8.56 (m, 1 H), 7.76-7.71 (m, 1 H), 7.42-7.35 (m, 1 H), 5.78 (d, 1 H), 4.08-3.98 (m, 1 H), 1 .21 -1.05 (m, 2H), 0.84 (t, 3H). B) 1 H NMR (400 MHz, CHCIg-of): 8.70-8.62 (m, 2H), 7.80-7.76 (m, 1 H), 7.42-7.35 (m, 1 H), 5.21 (d, 1 H), 3.75-3.68 (m, 1 H), 1 .89-1 .69 (m, 2H), 1 .05 (t, 3H).
Intermediate 8: 4-Methyl-5-pyridin-3-yl-oxazolidin-2-one
Figure imgf000042_0001
a) 2-Nitro-1 -pyridin-3-yl-propan-1 -ol
To a solution of LiAIH4 (2M in THF) (1.4 mL, 2.8 mmol) in dry THF (1 10 mL) at 0 °C, was slowly added 1 -nitroethane (2.00 mL, 28 mmol) under argon. After 20 min at 0 °C, nicotinaldehyde (2.64 mL, 28 mmol) was added in one portion. The mixture was stirred for 16 hours, while allowing the temperature to rise from 0 °C to room temperature. The reaction mixture was quenched by addition of 5 mL of 1 M HCI, followed by addition of CH2CI2 and Na2SC>4. The resulting suspension was stirred for 15 minutes and then filtered. The filtrate was concentrated. The residue was then purified by column chromatography (40 g of Si02) using EtOAc in hexane from 0% to 100% in order to give the product as an oil (3.2 g, 63%) as a mixture of diastereoisomers. LC-MS: [M+H] 183.4; Rt 0.41 min; (LCMS method 1 ). A) 1H NMR (400 MHz, CHCI3-d): 8.58-8.48 (m, 2H), 7.68 (d, 1 H) 7.33 - 7.23 (m, 1 H) 5.42-5.38 (m, 1 H), 4.70-4.60 (m, 1 H), 3.30-2.90 (brs, 1 H), 1.46 (d, 3H). B) 1H NMR (400 MHz, CHCI3-d): 8.58-8.48 (m, 2H), 7.68 (d, 1 H) 7.33 - 7.23 (m, 1 H) 5.04 (d, 1 H), 4.76-4.69 (m, 1 H), 3.30-2.90 (brs, 1 H), 1.31 (d, 3H). b) 4-Methyl-5-pyridin-3-yl-oxazolidin-2-one
A solution of 2-n i tro- 1 -py rid i n-3-yl-b uta n- 1 -ol (3.20 g, 17.6 mmol) in ethanol (90 mL) was purged with argon, and 200 mg of Raney-Nickel was added at room temperature. The reaction mixture was three times evacuated and refilled with hydrogen. The reaction was stirred for 16 hours under H2 at room temperature. Raney-Nickel was then filtered over Hyflo, and the Hyflo washed with EtOH. The filtrate was then concentrated in order to give 2-amino-1 -pyridin-3-yl-propan-1 -ol as a product (2.35 g, 88%), which was used in the next reaction step without purification. To a solution of 2-amino-1-pyridin-3-yl-propan- 1-ol (700 mg, 4.60 mmol) in CH2CI2 (20 mL) was added under argon Et3N (1 .60 mL, 1 1.5 mmol) at 0 °C, followed by triphosgene (819 mg, 2.76 mmol, dissolved in 5 mL of CH2CI2). The reaction temperature was allowed to warm from 0 °C to room temperature within one hour. The reaction mixture was then quenched with ice cold water and a 2 M solution of Na2C03, extracted with CH2CI2, dried over MgS04, filtered and concentrated. The residue was purified by column chromatography using EtOAc in hexane from 0% to 100 % in order to give the product (160 mg, 20%). LC-MS: [M+H] 179.1 ; Rt 0.31 min; (LCMS method 1 ).
Intermediate 9: (4S,5S)-4-((tert-Butyldiphenylsilyloxy)methyl)-5-phenyloxazolidin- 2-one
Figure imgf000044_0001
a) (4S,5S)-4-Hyd roxymethyl -5-phenyl -oxazol idi n-2-one
(1 S,2S)-2-Amino-1-phenylpropane-1 ,3-diol (20.0 g, 120 mmol), diethyl carbonate (29.7 mL, 245 mmol), and K2C03 (1.65 g, 12.0 mmol) were charged into a flask with mechanical stirrer and a vigreux-column. This suspension was heated in an oil bath at
135 °C, to give a yellow solution. The accrued EtOH was distilled off over the vigreux column. The reaction was stirred over a period of 3 h, until no more EtOH could be distilled off. The reaction mixture was then cooled to 50 °C, diluted with EtOAc and aqueous NaHC03. The organic layers were separated, washed with brine, dried over MgSCU, filtered, and concentrated. The residue was purified by column chromatography
(550 g Si02) using EtOAc in heptane from 33% to 100% in order to give the title compound as a beige oil (7.50 g, 33%). 1H NMR (400 MHz, DMSO-d6): 7.87 (br s, 1 H), 7.50-7.30 (m, 5H), 5.37 (d, 1 H), 5.23-5.17 (m, 1 H), 3.70-3.60 (m, 1 H), 3.60-3.50 (m, 2H). b) (4S,5S)-4-((tert-Butyldiphenylsilyloxy)methyl)-5-phenyloxazolidin-2-one
To a solution of (4S,5S)-4-hydroxymethyl-5-phenyl-oxazolidin-2-one (3.50 g, 17.2 mmol), NEta (4.80 mL, 34.4 mmol), and DMAP (105 mg, 861 μιηοΙ) in DMF (20 mL) was added dropwise TBDPSCI (4.86 mL, 18.9 mmol) at room temperature. The reaction was stirred for 3 hours at room temperature. The reaction mixture was then concentrated and diluted with TBME, the organic layers were separated, washed with aqueous NaHC03 and brine, dried over MgS04, and concentrated. The residue was purified by column chromatography (120 g Si02) using EtOAc in heptane from 0% to 60 % in order to give the title compound as a white solid (4.28 g, 57%). LC-MS: [M+H] 432.2; Rt 1.36 min; (LCMS method 2).
Intermediate 10: (4S,5S)-4-(((tert-Butvldiphenvlsilvl)oxv)methyl)-5-(4- methoxyphenyl)oxazolidin-2-one
Figure imgf000045_0001
To a solution of (4S,5S)-4-(hydroxymethyl)-5-(4-methoxyphenyl)oxazolidin-2-one
[545435-91-4] (0.68 g, 3.05 mmol) and imidazole (0.249 g, 3.66 mmol) in DMF (10 mL) was added dropwise TBDPSCI (0.97 mL, 3.66 mmol) at 0-5 °C. The reaction mixture was allowed to warm to RT and was stirred overnight at RT. The reaction mixture was concentrated and the residual oil was dissolved in TBME and washed with 10% aqueous KHS04, H20, saturated NaHC03 solution and brine, dried over MgS04, filtered and concentrated. The residue was purified by column chromatography using EtOAc in heptane from 5% to 50% in order to give the title compound as a white foam (1 .62 g, 55%). TLC (heptane/EtOAc 1 :1 ) Rf =0.44; LC-MS: [M+H] 462; Rt 1.36 min; (LCMS method 2). 1H NMR (400 MHz, CDCI3): 7.65 (d, 4H), 7.35-7.60 (m, 6H), 7.24 (d, 2H), 6.92 (d, 2H), 5.24 (d, 1 H), 5.20 (br s, 1 H), 3.84 (m, 4H), 3.77 (m, 2H), 1 .09 (s, 9H).
Intermediate 11 : (4S.5S)-4- ert-Butvldimethvlsilvhoxv)methvh-5-(4-(2- methoxyethoxy)phenyl)oxazolidin-2-one
Figure imgf000045_0002
a) (R)-Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-(2-ethoxyethoxy)phenyl) propanoate
To a suspension of (R)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4-hydroxyphenyl)- propanoate (4.43 g, 15.00 mmol), K2C03 (4.15 g, 30.0 mmol) and sodium iodide (1 12 mg, 750 μπιοΙ) in acetonitrile (100 mL) was added 1-bromo-2-methoxyethane (5.64 mL, 60.0 mmol) and the resulting mixture was stirred at reflux for 2 days. The reaction mixture was diluted with TBME and washed with H20 and brine. Combined extracts were dried over MgS04, filtered and concentrated to provide the title compound as a yellow oil (5.3 g, 95%). TLC (toluene/TBME 2:1 ) R, =0.44; tR = 1.084 min (UPLC 1 ); LC- MS: [M+H] 354; Rt 1.02 min; (LCMS method 2); 1H NMR (400 MHz, CDCI3): δ 7.05 (d,
2H), 6.88 (d, 2H), 4.96 (br d, 1 H), 4.58 (m, 1 H), 4.12 (dd, 2H), 3.76 (dd, 2H), 3.73 (s, 3H), 3.47 (s, 3H), 3.05 (m, 2H), 1.44 (s, 9H).
b) (4R,5S)-Methyl 5-(4-(2-methoxyethoxy)phenyl)-2-oxooxazolidine-4-carboxylate
To a solution of (R)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4-hydroxyphenyl)- propanoate (5.34 g, 14.35 mmol) in acetonitrile (260 mL) was added under argon a solution of potassium persulfate (7.76 g, 28.7 mmol) in H20 (190 mL) and a solution of CuS04 (0.458 g, 2.87 mmol) dissolved in H20 (70 mL). The resulting mixture was stirred for 3 h at 70 °C. The reaction mixture was extracted with EtOAc. Combined extracts were washed with brine, dried over MgS04, filtered and concentrated. The residue was purified by column chromatography using EtOAc in heptane from 20% to 100% in order to give the title compound as a yellow oil (2.33 g, 52%). TLC (heptane/EtOAc 1 :2) Rf =0.19; tR = 0.680 min (UPLC 1 ); LC-MS: [M+H] 296; Rt 0.68 min; (LCMS method 2); 1H NMR (400 MHz, CDCI3): 7.36 (d, 2H), 6.99 (d, 2H), 5.86 (br d, 1 H), 5.62 (d, 1 H), 4.30 (d,
1 H), 4.16 (dd, 2H), 3.88 (s, 3H), 3.79 (dd, 2H), 3.48 (s, 3H). c) (4S,5S)-4-(Hydroxymethyl)-5-(4-(2-methoxyethoxy)phenyl)oxazolidin-2-one
To a suspension of (4R,5S)-methyl 5-(4-(2-methoxyethoxy)phenyl)-2-oxooxazolidine-4- carboxylate (2.30 g, 7.79 mmol) in EtOH (45 mL) was added in portions at 0-5 °C sodium borohydride (648 mg, 17.1 mmol). The reaction mixture was stirred for 0.5 h at RT and then acidified with 4M aqueous HCI (10 mL) at 0-5 °C. The reaction mixture was concentrated and the product was extracted with EtOAc. Combined extracts were washed with brine, dried over MgSC^, filtered and concentrated to afford the title compound as a beige foam (1.80 g, 81 %). tR = 0.498 min (UPLC 1 ); LC-MS: [M+H] 268;
Rt 0.55 min; (LCMS method 2); 1H NMR (400 MHz, CDCI3): 7.31 (d, 2H), 6.96 (d, 2H), 6.45 (br s, 1 H), 5.33 (d, 1 H), 5.30 (br s, 1 H), 3.75-4.30 (m, 7H), 3.47 (s, 3H). d) (4S,5S)-4-(((tert-Butyldimethylsilyl)oxy)methyl)-5-(4-(2-methoxyethoxy)phenyl)- oxazolidin-2-one
The title compound was prepared in analogy to the procedure described for intermediate 10 [(4S,5S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-5-(4-methoxyphenyl)oxazolidin-2-one] from (4S,5S)-4-(hydroxymethyl)-5-(4-(2-methoxyethoxy)phenyl)oxazolidin-2-one and TBDMS-CI to afford after purification by column chromatography (using EtOAc in heptane from 5% to 50%) intermediate 11 as a light yellow oil. TLC (heptane/EtOAc 1 :1 ) Rf =0.26; tR = 1.28 min (UPLC 1 ); LC-MS: [M+H] 382.2; Rt 1.17 min; (LCMS method 2); 1H NMR (400 MHz, CDCI3): 7.30 (d, 2H), 6.97 (d, 2H), 5.44 (br s, 1 H), 5.23 (d, 1 H), 4.18 (dd, 2H), 3.70-3.85 (m, 5H), 3.48 (s, 3H), 0.91 (s, 9H), 0.11 (s, 6H).
Intermediate 12: (4S,5S)-5-(4-(2-((tert-Butvldimethvlsilvl)oxv¾ethoxv)phenyl)-4- (((tert-butyldimethylsilyl)oxy)methyl)oxazolidin-2-one
Figure imgf000047_0001
The title compound was prepared in analogy to the procedure described for intermediate 11 starting with (R)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4- hydroxyphenyl)propanoate and (2-bromoethoxy)(tert-butyl)dimethylsilane. TLC
(heptane/EtOAc 1 :1 ) Rf =0.51 ; tR = 1.764 min (UPLC 1 ); LC-MS: [M+H] 482; Rt 1.57 min; (LCMS method 1 ); 1H NMR (400 MHz, CDCI3): 7.31 (d, 2H), 6.96 (d, 2H), 5.26 (br s, 1 H), 5.22 (d, 1 H), 4.13 (m, 2H), 4.00 (m, 2H), 3.79 (m, 1 H), 3.67 (m, 2H), 0.93 (s, 9H), 0.92 (s, 9H), 0.11 (m, 12H).
Intermediate 13: (4S.5S)-4- ert-Butvldimethvlsilvhoxv)methvh-5-(4-(3-iaert- butyldimethylsilyl)oxy)propoxy)phenyl)oxazolidin-2-one
Figure imgf000047_0002
The title compound was prepared in analogy to the procedure described for intermediate 12 starting with (R)-methyl 2-((tert-butoxycarbonyl)amino)-3-(4- hydroxyphenyl)propanoate and (3-bromopropoxy)(tert-butyl)dimethylsilane. TLC
(heptane/EtOAc 1 :1 ) Rf =0.49; tR = 1.832 min (UPLC 1 ); LC-MS: [M+H] 496; Rt 1.62 min (LC-MS method 1 ); 1 H NMR (400 MHz, CDCI3): 7.30 (d, 2H), 6.95 (d, 2H), 5.27 (br s, 1 H), 5.22 (d, 1 H), 4.13 (dd, 2H), 4.00 (m, 2H), 3.80 (m, 3H), 3.74 (m, 2H), 2.01 (m, 2H), 0.93 (s, 9H), 0.91 (s, 9H), 0.10 (s, 6H), 0.06 (s, 6H).
Intermediate 14: (4S, 5R)-4-Methyl-5-thiazol-2-yl-oxazolidin-2-one
Figure imgf000048_0001
a) (2-Hydroxy-1 -methyl-2-thiazol-2-yl-ethyl)-carbamic acid tert-butyl ester
Boc-L-alanal (9.99 g, 57.7 mmol) was dissolved in 200 mL of CH2CI2. 2-(trimethylsilyl)- thiazole (9.90 g, 62.9 mmol) dissolved in 70 mL of CH2CI2 was added to the reaction mixture at -20 °C under argon. After 21 hours at -20 °C, the reaction mixture was concentrated. The residue was then dissolved in 180 mL of THF, when TBAF (1 M in THF, 63.4 mL, 63.4 mmol) was added, and the reaction mixture was stirred for 4 hours at room temperature. The reaction mixture was then concentrated. The residue was purified by column chromatography (120 g Si02) using EtOAc in hexane from 0% to 100 % in order to give the title compound as a diastereomeric mixture (14.0 g, 93%). LC-MS: [M+H] 259.2; Rt 0.78 min; (LCMS method 1 ). b) 2-Amino-1 -thiazol-2-yl-propan-1 -ol
2-Hydroxy-1-methyl-2-thiazol-2-yl-ethyl)-carbamic acid tert-butyl ester (13.8 g, 53.4 mmol) was dissolved in 50 mL of dioxane. 134 mL (534 mmol) of 4M HCI in dioxane was added, and the reaction mixture was stirred for 4 hours at room temperature. The reaction mixture was then concentrated, and the residue was diluted with diethyl ether and filtered in order to gain the title compound as a white salt as a diastereomeric mixture (11.5 g, 92%). LC-MS: [M+H] 159.1 ; Rt 0.22 min; (LCMS method 1 ). c) (4S, 5R)-4-Methyl-5-thiazol-2-yl-oxazolidin-2-one
A mixture of diastereoisomers of 2-amino-1-thiazol-2-yl-propan-1-ol (4.20 g, 18.2 mmol) was dissolved in 160 mL of CH2CI2. Diisopropylethylamine (11.1 mL, 63.6 mmol) was added at 0 °C, followed by triphosgene (2.70 g, 9.09 mmol) dissolved in 40 mL of CH2CI2. The reaction mixture was stirred at room temperature for 2 hours and then diluted with CH2CI2. The organic solvents were separated, washed with aqueous NaHC03 and brine, dried over MgS04, filtered, and concentrated. The residue was purified by column chromatography (80 g Si02) using EtOAc in hexane from 0% to 100 % in order to give the title compound as a single enantiomer (2.16 g, 64%). LC-MS: [M+H] 185.3; Rt 0.45 min; (LCMS method 1 ). 1H NMR (400 MHz, CHCI3-d): 7.75 (d, 1 H), 7.35 (d, 1 H), 5.60 (br s, 1 H), 5.32 (d, 1 H), 4.18-4.09 (m, 1 H), 1.45 (d, 3H).
Intermediate 15: (4S, 5S)-4-Methyl-5-thiazol-2-yl-oxazolidin-2-one
Figure imgf000049_0001
To a mixture of (1 S,2S)-2-amino-1 -thiazol-2-yl-propan-1-ol and (1 R,2S)-2-amino-1 - thiazol-2-yl-propan-1-ol (2.9 g, 12.5 mmol) in CH2CI2 (40 mL) was added under argon NEt3 (10.5 mL, 75 mmol) at 0 °C. Then, triphosgene (1.86 g, 6.27 mmol) dissolved in 40 mL of CH2CI2 was added slowly, and the temperature was allowed to warm from 0 °C to room temperature. The reaction mixture was stirred for 16 hours at room temperature.
The reaction mixture was then quenched by addition of aqueous NaHC03. The organic layers were separated, dried over MgS04, filtered, and concentrated. The residue was purified by column chromatography using EtOAc in heptane from 0% to 100% in order to give the desired product (330 mg, 13%). LC-MS: [M+H] 185.0; Rt 0.48 min; (LCMS method 1 ). 1H NMR (400 MHz, CHCI3-c ): 7.79 (d, H), 7.34 (d, 1 H), 5.91 (d, 1 H), 5.71
(br s, 1 H), 4.48-4.38 (m, 1 H), 0.89 (d, 3H).
Synthesis of Example compounds
Example 1 : (4S,5R)-3-(2'-Amino-2-morpholin-4-yl-4,-trifluoromethyl- ^jS'lbipyrimidinyl-e-ylJ^-methyl-S-thiazol^-yl-oxazolidin^-one
Figure imgf000050_0001
a) (4S,5R)-3-(6-Chloro-2-morpholin-4-yl-pyrimidin-4-yl)-4-methyl-5-thiazol-2-yl- oxazolidin-2-one
(4S, 5R)-4-Methyl-5-thiazol-2-yl-oxazolidin-2-one (intermediate 14) (4.70 g, 20.1 mmol) was dissolved in 70 mL of DMF and cooled to 0 °C. NaH (964 mg, 60% in oil, 24.1 mmol) was added under argon, and the reaction mixture was stirred for 30 minutes at 0 °C. 4-(4,6-dichloropyrimidin-2-yl)morpholine (3.70 g, 20.1 mmol) dissolved in 30 mL of DMF was added, and the reaction mixture was stirred for 3 hours at 0 °C, followed by stirring at RT for 2 hours. The reaction was then quenched by addition of aqueous NH4CI, followed by dilution with EtOAc; the organic solvents were separated, washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by column chromatography (80 g S1O2) using EtOAc in hexane from 0% to 100 % in order to give the title compound (3.64 g, 48%). LC-MS: [M+H] 382.2, 384.1 ; Rt 1.10 min; (LCMS method 1 ). 1H NMR (400 MHz, CHCI3-d): 7.77 (d, 1 H), 7.38-7.33 (m, 2H), 5.39 (d, 1 H), 5.07-4.98 (m, 1 H), 3.75-3.55 (m, 8H), 1.64 (d, 3H). b) (4S,5R)-3-(2'-Amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5,]bipyrimidinyl-6-yl)- 4-methyl-5-thiazol-2-yl-oxazolidin-2-one
To a solution of (4S,5R)-3-(6-chloro-2-morpholin-4-yl-pyrimidin-4-yl)-4-methyl-5-thiazol- 2-yl-oxazolidin-2-one obtained in step a) (1.30 g, 3.40 mmol) in 20 mL of
dimethoxyethane was added under argon 5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl)-4-(trifluoromethyl)pyrimidin-2-amine (1 .08 g, 3.75 mmol), PdCI2(dppf)-CH2CI2 (214 mg, 262 μηιοΙ), and 2 M aqueous sodium carbonate (5.11 mL, 10.2 mmol). The reaction mixture was stirred at 80 °C for 30 minutes. The reaction mixture was then cooled to RT and diluted with 80 mL of EtOAc, the organic solvents were washed with aqueous NH4CI and brine, dried over MgS04, filtered, and concentrated. The residue was purified by column chromatography (80 g Si02) using EtOAc in hexane from 0% to 100 % in order to give example 1 as an amorphous solid (1.20 g, 69%). LC-MS: [M+H] 509.0; Rt 0.99 min; (LCMS method 1 ). 1H NMR (400 MHz, DMSO-d6): 8.58 (s, 1 H), 7.92 (d, 1 H), 7.87 (d, 1 H), 7.64 (br s, 2H), 7.41 (s, 1 H), 5.89 (d, 1 H), 5.10-5.04 (m, 1 H), 3.75-3.55 (m, 8H), 1.62 (d, 3H). Example 2: (4S*.5S*)-3-(2'-amino-2-morpholino-4'-(trifluoromethvn-r4.5'- bipyrimidin]-6-yl)-4 -ethyl -5-(4-methoxyphenyl)oxazolidin-2-one
Figure imgf000051_0001
a) (4S*,5S*)-3-(6-Chloro-2-morpholinopyrimidin-4-yl)-4-ethyl-5-(4-methoxyphenyl) oxazolidin-2-one
To a solution of (4R*,5R*)-4-ethyl-5-(4-methoxyphenyl)oxazolidin-2-one (intermediate 2)
(217 mg, 0.98 mmol) in DMF (2 mL) was added at room temperature under argon NaH (51.4 mg, 1.18 mmol). After 20 minutes, a suspension of 4-(4,6-dichloropyrimidin-2- yl)morpholine (230 mg, 0.98 mmol in DMF (1 mL) was added, and the reaction mixture was stirred at 85 °C for 20 minutes. The solution was quenched at 0 °C with aqueous NH4CI, extracted with ethyl acetate, and the organic layers were dried over Na2S04, filtered and concentrated. The crude product was purified by column chromatography using EtOAc in hexane from 0% to 20% in order to give the title compound as a white solid (375 mg, 91 %). LC-MS: [M+H] 419.1 ; Rt 1.26 min; (LCMS method 1 ). b) (4S 5S*)-3-(2,-Amino-2-morpholino-4,-(t^
ethyl-5-(4-methoxyphenyl)oxazolidin-2-one
To a solution of (4R*,5R*)-3-(6-chloro-2-morpholinopyrimidin-4-yl)-4-ethyl-5-(4- methoxyphenyl) oxazolidin-2-one obtained in step a) in DME (2 mL) was added at room temperature under argon 5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-4- (trifluoromethyl)pyrimidin-2-amine (76 mg, 0.26 mmol), a solution of 2M aqueous Na2C03 (0.36 mL, 0.72 mmol) and tetrakis(triphenylphosphine)palladium (27.6 mg, 24 μιτιοΙ). The mixture was stirred at 80 °C for 1 hour, cooled to RT and concentrated. The residue was purified by column chromatography using EtOAc in hexane from 0% to 20 % in order to give the title compound (125 mg, 95%) as a yellow oil. LC-MS: [M+H] 546.2; Rt 1.17 min; (LCMS method 1 ). 1H NMR (400 MHz, CHCI3- ): 8.63 (s, 1 H), 7.68 (s, 1 H), 7.31 (d, 2H), 6.96 (d, 2H), 5.49 (br s, 2H), 5.27 (d, 1 H), 4.66-4.61 (m, 1 H), 3.84 (s, 3H), 3.80-3.73 (m, 8H), 2.30-2.00 (m, 2H), 1 .08 (t, 3H).
Example 3: (4S,5S)-3-(2'-Amino-2-morpholino-4'-(trifluoromethvl)-r4,5'- bipyrimidin]-6-yl)-4-(hydroxymethyl)-5-(4-methoxyphenyl)oxazolidin-2-one
Figure imgf000052_0001
a) (4S,5S)-4-(((tert-Butyldiphenylsilyl)oxy)methyl)-3-(6-chloro-2- morpholinopyrimidin-4-yl)-5-(4-methoxyphenyl)oxazolidin-2-one
To a solution of (4S,5S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-5-(4-methoxyphenyl)- oxazolidin-2-one (intermediate 10) (1 .65 g, 3.57 mmol), 4-(4,6-dichloropyrimidin-2-yl)- morpholine (920 mg, 3.93 mmol) and Cs2C03 (1 .75 g, 5.36 mmol) in dioxane (20 ml_) was added after purging with argon 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (145 mg, 250 pmol) and Pd2(dba)3 (65 mg, 0.071 mmol), and the reaction mixture was heated for 5 h at 100 °C. The reaction mixture was added to 10% aqueous NaHC03 solution and extracted with EtOAc. Combined extracts were washed with brine, dried over MgS04, filtered and concentrated. The residue was purified by column
chromatography using EtOAc in heptane from 0% to 50 % in order to give the title compound as a white solid (2.33 g, 94%). TLC (heptane/EtOAc 1 : 1 ) Rf =0.52; LC-MS: [M+H] 659,661 ; Rt 1.58 min; (LCMS method 2). 1 H NMR (400 MHz, CDCI3): 7.64 (m, 4H), 7.54 (s, 1 H), 7.55-7.35 (m, 6H), 7.26 (m, 2H), 6.95 (d, 2H), 5.21 (d, 1 H), 4.56 (m, 1 H), 4.22 (dd, 1 H), 3.96 (dd, 1 H), 3.84 (s, 3H), 3.60-3.40 (m, 8H), 1 .09 (s, 9H). b) (4S,5S)-3-(2,-Amino-2-morpholino-4,-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4- (((tert-butyldiphenylsilyl)oxy)methyl)-5-(4-methoxyphenyl)oxazolidin-2-one
A solution of (4S,5S)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-3-(6-chloro-2- morpholinopyrimidin-4-yl)-5-(4-methoxyphenyl)oxazolidin-2-one obtained in step a) (150 mg, 228 μιτιοΙ), 5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-4-(trifluoro- methyl)pyrimidin-2-amine (108 mg, 364 pmol), 20% aqueous Na2C03 (0.24 ml_, 2.28 mmol), and PdCI2(dppf)-CH2CI2 (18.6 mg, 23 pmol) in DME (2 mL) under argon was stirred at 80 °C for 8 h. The reaction mixture was diluted with EtOAc and washed with saturated NaHC03 solution, H20 and brine, dried over MgSC , filtered and concentrated. The residue was purified by column chromatography using EtOAc in heptane from 0% to 33% in order to give the title compound as a light yellow foam (68 mg, 28%): TLC (heptane/EtOAc 1 :1 ) Rf =0.32; tR = 1.663 min (UPLC 1 ); LC-MS: [M+H] 786; Rt 1.48 min; (LCMS method 2). c) (4S,5S)-3-(2'-Amino-2-morpholino-4,-(trifluoromethyl)-[4,5,-bipyrimidin
(hydroxymethyl)-5-(4-methoxyphenyl)oxazolidin-2-one
To a solution of (4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6- yl)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-5-(4-methoxyphenyl)oxazolidin-2-one obtained in step b) (68 mg, 65 μπιοΙ) in THF (2 mL) was added dopwise at 0 °C 1 M TBAF in THF (0.05 ml, 0.05 mmol), and the resulting mixture was stirred for 30 min at 0 °C and 1 h at RT. The reaction mixture was concentrated, and the residue was purified by column chromatography using a ratio of hexane/CH2CI2/MeOH from 100:100:5 to 0:100:5, followed by preparative HPLC (Waters Sun Fire C18, 30 x 100mm, 5 urn; 0.1 % TFA- water/acetonitrile; gradient acetonitrile 30-50% in 20 min) to afford the title compound as white solid (18 mg, 50%); TLC (CH2CI2/MeOH 19:1 ) Rf =0.40; tR = 0.998 min (UPLC 1 ); LC-MS: [M+H] 548; Rt 0.96 min; (LCMS method 2). 1H NMR (600 MHz, DMSO-d6): 8.60 (s, 1 H), 7.64 (br s, 2H), 7.53 (s, 1 H), 7.34 (d, 2H), 7.00 (d, 2H), 5.58 (d, 1 H), 5.32 (t, 1 H), 4,59 (m, 1 H), 4.00 (m, 1 H), 3.82 (m, 1 H), 3.76 (s, 3H), 3.75-3.55 (m, 8H).
Examples 4 to 14
Examples 4 to 14 in Table 1 below can be made using procedures analogous to those described in examples 1-3, using the appropriate boronic ester intermediate and oxazolidinone.
Table 1
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
hydroxypropoxy)phenyl)oxazolidin-2-one (m, 2H), 1 .85 (m,
2H).
Biological activity
The activity of a compound according to the present invention can be assessed by the following in vitro & in vivo methods
Preparation of compound dilutions (384-well)
Test compounds were dissolved in DMSO (10 mM) and transferred into 1.4 mL flat bottom or V-shaped Matrix tubes carrying a unique 2D matrix chip by individual Novartis compound hubs. The numbers of these chips were distinctively linked to Novartis Pharma Numbers. The stock solutions were stored at -20°C if not used immediately. For the test procedure the vials were defrosted and identified by a scanner whereby a working sheet was generated that guided the subsequent working steps.
Compounds were either manually diluted in DMSO for individual experiments (96 wells enabling 10 cpds at 8 (single points) concentrations) as described in or prepared as described below if tested for profiling in 384-wells. This format enabled the assay of maximally 40 individual test compounds at 8 concentrations (single points) including 4 reference compounds. The dilution protocol included the production of "pre-dilution plates", "master plates" and "assay plates".
Pre-dilution plates: 96 polypropylene well plates were used as pre-dilution plates. A total of 4 pre-dilution plates were prepared including 10 test compounds each on the plate positions A1-A10, one standard compound at A1 1 and one DMSO control at A12. The pattern of the dilution steps is summarized in Table 1. Programs have been written to run these pipetting steps on the HamiltonSTAR robots.
Table 1 Dilution pattern for pre-dilution plates c Vol Cone. Vol Vol Cone Dil. Final concentration (uL) (μΜ) (uL) (uL) (μΜ) ratio (μΜ)
DMSO
A 30 10Ό0 + 135 → 165 1 '820 1 :5.5 10
0
B 50 1 '820 + 1 16 → 166 546 1 3.33 3
C 50 546 + 100 → 150 182 1 3 1
D 50 182 + 1 16 → 166 54.6 1 3.33 0.3
E 50 54.6 + 100 → 150 18.2 1 3 0.1
F 50 18.2 + 1 16 → 166 5.46 1 3.33 0.03
G 50 5.46 + 100 → 150 1.82 1 3 0.01
H 50 1 .82 + 1 16 → 166 0.546 1 3.33 0.003
DMSO was saturated with H20 to a concentration of 10%. Vol: Volume, Cone:
Concentration, Dil. ratio: Dilution ratio, Fin. c: Final concentration. Master plates: 100μΙ_ of individual compound dilutions including standard compound and controls of the 4 "pre-dilution plates" were transferred into a 384 "master plate" including the following concentrations 1 '820, 564, 182, 54.6, 18.2, 5.46, 1.82 and 0.546μΜ, respectively in 90 % DMSO.
Assay plates: Identical "assay plates" were then prepared by pipetting 50nl_ each of compound dilutions of the "master plates" into 384-well "assay plates". The compounds were mixed with 4.5μΙ_ of assays components plus 4.5μΙ_ enzyme corresponding to a 1 :181 dilution enabling the final concentration of 10, 3.0, 1.0, 0.3, 0.1 , 0.03, 0.01 and 0.003 μΜ, respectively. The preparation of the "master plates" was handled by the Matrix PlateMate Plus robot and replication of "assay plates" by the HummingBird robot.
Method to generate expression constructs
Catalytically active human ΡΙ3Κα, ΡΙ3Κβ, PI3K5, and mTOR were cloned, expressed and purtified as described (Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, de Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C (2008), Mol Cancer Ther.
7:1851 -63 and Maira SM, Pecchi S, Brueggen J, Huh K, Schnell C, Fritsch C, Nagel T, Wiesmann M, Brachmann S, Dorsch M, Chene P, Schoemaker K, De Pover A, Menezes D, Fabbro D, Sellers W, Garcia-Echeverria C, Voliva CF (201 1 ), Mol. Cancer Ther. accepted).
Biochemical assays for PI3Kalpha, PI3Kbeta
The luminescence-based ATP detection reagent KinaseGlo was obtained from
Promega, (Cat. No. V6714, Lot No. 236161 ) through Catalys, Wallisellen, Switzerland. (L-alpha-phosphatidylinositol (PI), Liver, Bovine) were obtained from Avanti Polar Lipid (Cat. No. 840042C, Lot#LPI-274), Phosphatidylinositol-4,5-bisphosphate (PIP(4,5)2
(Avanti, Cat. No. 840046X) or L-a-phosphatidylinositol (PI) was obtained from Avanti Polar Lipid (Cat. No. 840042C, Lot#LPI-274). L-a-Phosphatidylserine (PS) was from Avanti Polar Lipid (Cat. No. 840032C), n-Octylglucoside Avanti Polar Lipid (Cat. No. 10634425001 ). Luminescence is a well established readout to determine ATP concentrations and can thus be used to follow the activity of many kinases regardless of their substrate. The Kinase Glo Luminescent Kinase Assay (Promega, Madison/WI, USA) is a homogeneous HTS method of measuring kinase activity by quantifying the amount of ATP remaining in solution following a kinase reaction.
50 nL of compound dilutions were dispensed onto black 384-well low volume Non Binding Styrene (NBS) plates (Costar Cat. No. NBS#3676) as described in section 8.2. L-ophosphatidylinositol (PI), provided as 10 mg/ml solution in methanol, was transferred into a glass tube and dried under nitrogen beam. It was then resuspended in 3%
OctylGlucoside by vortexing and stored at 4°C. 5 μΙ_ of a mix of PI/OG with the PI3Ka and Pi3Kb subtypes were added. Kinase reactions were started by addition of 5 μΙ of ATP-mix containing in a final volume 10 μΙ_ 10 mM TRIS-HCI pH 7.5, 3mM MgCI2, 50 mM NaCI, 0.05% CHAPS, 1 mM DTT and 1 μΜ ATP, and occured at room temperature. Reactions were stopped with 10 μΙ of KinaseGlo and plates were read 10 mins later in a Synergy2 reader using an integration time of 0.1 seconds per well. 2.5 μΜ of NVP- BGT226 (standard) was added to the assay plates to generate the 100% inhibition of the kinase reaction, and the 0% inhibition was given by the solvent vehicle (90% DMSO in water). NVP-BGT226 was used as a reference compound and included in all assay plates in the form of 16 dilution points in duplicate.
IC50 values of the percentage inhibition of each compound at 8 concentrations (usually 10, 3.0, 1.0, 0.3, 0.1 , 0.030, 0.010 and 0.003 μΜ) n=2 were derived by fitting a sigmoidal dose-response curve to a plot of assay readout over inhibitor concentration as described. All fits were performed with the program XLfit4 (ID Business Solutions, Guildford, UK).
Biochemical assays for PI3Kdelta, PI3Kgamma
The TR-FRET Adapta™ Universal Kinase Assay Kit was purchased from Invitrogen
Corporation (Carlsbad/CA, USA) (Cat. No. PV5099). The kit contains the following reagents: Adapta Eu-anti-ADP Antibody (Europium labeled anti-ADP antibody in HEPES buffered saline, Cat. No. PV5097), Alexa Fluor® 647-labeled ADP tracer (Alexa Fluor® 647-labeled ADP tracer in HEPES buffered saline, Cat. No. PV5098), proprietary TR- FRET dilution buffer pH 7.5 (Cat. No. PV3574).
PIK3CD substrate Phosphatidylinositol was obtained from Invitrogen (vesicules consisting of 2 mM PI in 50mM HEPES pH7.5; Cat. No. PV5371 ). PIK3CG substrate Phosphatidylinositol-4,5-bisphosphate (PIP(4,5)2 was obtained from Invitrogen (PIP2:PS large unilamellar vesicules consisting of 1 mM PIP2: 19mM PS in 50mM HEPES pH7.5, 3mM MgCI2, 1 mM EGTA; Cat. No. PV5100).
Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) is a technology based on energy transfer between two adjacent dyes, from an excited electron in one dye (the donor) to an electron of an adjacent dye (the acceptor) through resonance, then released as a photon. This energy transfer is detected by an increase in the
fluorescence emission of the acceptor, and a decrease in the fluorescence emission of the donor. TR-FRET assays for protein kinases use a long-lifetime lanthanide Terbium or Europium chelates as the donor species which overcome interference from compound autofluorescence or light scatter from precipitated compounds, by introducing a delay after excitation by a flashlamp excitation source. Results are often expressed as a ratio of the intensities of the acceptor and donor fluorophores. The ratiometric nature of such a value corrects for differences in assay volumes between wells, as well as corrects for quenching effects due to colored compounds. The Adapta™ assay can be divided into two phases : a kinase reaction phase and an ADP detection phase. In the kinase reaction phase, all kinase reaction components are added to the well and the reaction is allowed to incubate for a set period of time specific for each kinase. After the reaction, a detection solution of Eu-labeled anti-ADP antibody, Alexa Fluor® 647-labeled ADP tracer, and EDTA (to stop the kinase reaction) are added to the assay well. ADP formed by the kinase reaction will displace the Alexa Fluor® 647-labeled ADP tracer from the antibody, resulting in a decrease in TR-FRET signal. In the presence of an inhibitor, the amount of ADP formed by the kinase reaction is reduced, and the resulting intact antibody-tracer interaction maintains a high TR-FRET signal. In the Adapta™ assay, the donor (Europium-anti-ADP antibody) is excited at 340nm and will transfer its energy to the acceptor (Alexa Fluor® 647-labeled ADP tracer). The emission from the Alexa Fluor® 647 can be monitored with a filter centered at 665 nm because it is located between the emission peaks of the donor, which is measured at 615/620 nm.
50 nl_ of compound dilutions were dispensed onto white 384-well small volume polystyrene plate as described in section 2.2. Then 5 μΙ_ of PI3Kg and PI3Kd and lipid substrate (PI or PIP2:PS) followed by 5 μΙ_ of ATP (final assay volume 10 μΙ_) are incubated at RT. The standard reaction buffer for the Adapta™ TR-FRET assay contained 10mM Tris-HCI pH 7.5, 3mM MgCI2, 50mM NaCI, 1 mM DTT, 0.05% CHAPS. Reactions were stopped with 5 μΙ_ of a mixture of EDTA containing the Eu-labeled anti-
ADP antibody and the Alexa Fluor® 647-labeled ADP tracer in TR-FRET dilution buffer (proprietary to IVG). Plates are read 15 to 60 mins later in a Synergy2 reader using an integration time of 0.4 seconds and a delay of 0.05 seconds. Control for the 100% inhibition of the kinase reaction was performed by replacing the PI3K by the standard reaction buffer. The control for the 0% inhibition was given by the solvent vehicle of the compounds (90% DMSO in H20). The standard compound NVP-BGT226 was used as a reference compound and included in all assay plates in the form of 16 dilution points in duplicate.
Data are analyzed using Excel fit software or Graphpad Prism. EC50 values were derived by fitting a sigmoidal dose-response curve to a plot of assay readout over inhibitor concentration. All fits were performed with the program XLfit4 (ID Business Solutions, Guildford, UK). Determination of EC50 values of the percentage inhibition of each compound at 8 concentrations (usually 10, 3.0, 1.0, 0.3, 0.1 , 0.030, 0.010 and 0.003 μΜ) n=2 were derived by fitting a sigmoidal dose-response curve to a plot of assay readout over inhibitor concentration. All fits were performed with the program XLfit4 (ID Business Solutions, Guildford, UK).
Biochemical assay for mTOR
TR-FRET assays for protein kinases uses a long-lifetime lanthanide Terbium or
Europium chelates as the donor species which overcome interference by compound autofluorescence or light scatter from precipitated compounds, by introducing a delay after excitation by a flashlamp excitation source. Results are often expressed as a ratio of the intensities of the acceptor and donor fluorophores. The ratiometric nature of such a value corrects for differences in assay volumes between wells, as well as corrects for quenching effects due to colored compounds.
Binding Assays are based on the binding and displacement of an Alexa Fluor® 647- labeled, ATP-competitive kinase inhibitors to the kinase of interest. Invitrogen's "Kinase
Tracers" have been developed to address a wide range of kinase targets and are based on ATP-competitive kinase inhibitors, making them suitable for detection of any compounds that bind to the ATP site or to an allosteric site altering the conformation of the ATP site. Inhibitors that bind the ATP site include both Type I kinase inhibitors, which bind solely to the ATP site, and Type II inhibitors (e.g., Gleevec®/lmatinib, Sorafenib,
BIRB-796), which bind to both the ATP site and a hydrophobic site exposed in the DFG- out (non-active) conformation. Type III inhibitors are compounds that do not compete with ATP are loosely referred to as allosteric inhibitors. A study of 15 diverse Type III inhibitors demonstrated that all but one compound was detected in the binding assay with equivalent potency to activity assays. The sole exception was a substrate- competitive compound, and thus not a true allosteric inhibitor.
In contrast to most fluorescence-based kinase activity assays, LanthaScreen® Eu3+ Kinase Binding Assays can be read continuously, which facilitates evaluation of compounds with slow binding kinetics. Also, unlike most activity assays, binding assays can be performed using either active or non-activated kinase preparations, which enables characterization of compounds that bind preferentially to non-activated kinases, such as Gleevec®/imatinib and some allosteric inhibitors.
In the Lanthascreen™ kinase binding assay, the donor (Eu3+-anti-GST antibody) is excited at 340nm and will transfer its energy to the acceptor (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor = Tracer-314). The emission from the Tracer-314
(Alexa Fluor® 647 inhibitor) can be monitored with a filter centered at 665 nm because it is located between the emission peaks of the donor, which is measured at 615/620 nm. The binding of both, the Tracer-314 and Eu3+-anti-GST antibody, to the kinase results in a high degree of FRET from the Eu3+-donor fluorophore to the Alexa-Fluor® 647- acceptor fluorophore on the Tracer-314. Binding of an inhibitor to the kinase competes for binding with the tracer, resulting in a loss of FRET.
50 nl_ of compound dilutions were dispensed onto white 384-well small volume polystyrene plate as described in section 2.2. Then 5 μΙ_ of GST-mTOR and Europium- anti-GST antibody followed by 5 pL of tracer-314 (final assay volume 10 μΙ_) are incubated at RT. The standard reaction buffer for the Lanthascreen™ kinase binding assay contained 50mM HEPES pH 7.5, 5mM MgCI2, 1 mM EGTA, 0.01 % Pluronic F-
127. Plates are read 60 mins later in a Synergy2 reader using an integration time of 0.2 microseconds and a delay of 0.1 microseconds.
To calculate the emission ratio, the signal emitted at 665 nm from the acceptor (Alexa Fluor® 647-labeled Tracer-314) is divided by the signal emitted at 620 nm from the donor (Eu3+anti-GST antibody)
Control for the 0% inhibition was given by the solvent vehicle of the compounds (90% DMSO in H20). Control for the relative 100% inhibition was performed by adding 10 μΜ in the mix containing GST-mTOR and Europium anti-GST antibody. An additional control for the absolute 0% inhibition is given by Eu3+anti-GST antibody without GST-mTOR.
Cellular assays for PI3Kalpha, beta and delta
AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay, ALPHA, Perkin Elmer) is a non-radioactive bead-based proximity assay technology to study
biomolecular interactions in a homogenous microtiter plate format. The brand name SureFire denotes AlphaScreen assays that are adapted to quantify the phosphorylation of endogenous cellular proteins in cell lysates, by using matched antibody pairs, which consist of an anti-phospho-kinase and an anti-kinase antibody. The assay allows characterization of kinase signaling in cells as well as measurement of kinase inhibitor effects. The AlphaScreen technology provides several advantages over standard assay techniques such as ELISA, as it avoids time-consuming washing procedures and reduces plate handling. Furthermore, it is miniaturizable at least to a 384-well format and provides sensitivity down to the femtomolar range, dependent on the affinity of the antibodies included in the individual AlphaScreen SureFire assay kit. High sensitivity is reached by an intrinsic amplification mechanism, which involves production of singlet oxygen molecules. SureFire assay kits are commercially available for specific targets and include pairs of validated antibodies (PerkinElmer). This report describes common procedures applied for AlphaScreen SureFire assays and respective semi-automated steps for routine kinase inhibitor profiling in cell-based assays.
The Rat-1 cell lines stably overexpressing activated PI3K class I isoforms Rat-1 pBABEpuro Myr-HA-hp1 10 delta (Rat-1_PI3Kdelta) and Rat-1 pBABEpuro Myr-HA- hpH Oalpha (Rat-1_PI3Kalpha) and Rat-1 pBABEpuro Myr-HA-hp1 10 beta (Rat- 1_PI3beta) were prepared as described (Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, de Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C (2008), Mol Cancer Ther. 7:1851 -63 and Maira SM, Pecchi S, Brueggen J, Huh K, Schnell C, Fritsch
C, Nagel T, Wiesmann M, Brachmann S, Dorsch M, Chene P, Schoemaker K, De Pover A, Menezes D, Fabbro D, Sellers W, Garcia-Echeverria C, Voliva CF (201 1 ), Mol.
Cancer Ther., accepted). All cell lines were cultivated in complete growth medium (DMEM high glucose, 10% (v/v) fetal bovine serum, 1 % (v/v) MEM NEAA, 10mM HEPES, 2mM L-glutamine, puromycin (10 μg/mL for Rat-1_PI3Kdelta and Rat-
1_PI3Kalpha, 4 ug/mL for Rat-1_PI3beta), 1 % (v/v) Pen/Strep) to 90 % confluency at 37°C / 5 % C02 / 90 % humidity in a humidified C02 incubator and were split twice a week.
The following materials were used for p-AKT(S473) detection in Rat-1 cell lysates:
Dulbecco's modified Eagle's medium (DMEM) high glucose (Gibco Invitrogen, Basel,
Switzerland, Cat. No. 41965), Heat Inactivated Fetal Bovine Serum, Qualified (HI FBS; Gibco Invitrogen, Basel, Switzerland, Lot. No. 16140), MEM non essential amino acids (NEAA; Gibco Invitrogen, Basel, Switzerland, Cat. No. 11 140), HEPES (Gibco
Invitrogen, Basel, Switzerland, Cat. No. 15630), Penicillin/Streptomycin (Pen/Strep, 100x; Gibco Invitrogen, Basel, Switzerland, Cat. No. 15140-122), L-Glutamine (Gibco
Invitrogen, Basel, Switzerland, Cat. No. 25030), Puromycin (Sigma Aldrich, Buchs, Switzerland, Cat. No. P9620), DMSO (MERCK, Dietikon, Switzerland, Cat. No.
8.02912.2500), H20, MilliQ- H20 unless otherwise stated (MILLIPORE QGARDOOR1 , Millipore, Zug, Switzerland ), Bovine serum albumine (BSA; Sigma Aldrich, Buchs, Switzerland Cat. No. A8412), SureFire p-Akt 1/2 (Ser473) Assay Kit (PerkinElmer,
Schwerzenbach, Switzerland, Cat. No. TGRAS50K).
The p-Akt(S473) SureFire assay measures the phosphorylation of endogenous cellular Akt 1/2 at Ser473 in cell lysates. Using Rat-1 cells stably expressing myr-HA-tagged versions of the human PI3Kdelta, PI3Kalpha, or PI3Kbeta p110 catalytic subunit isoforms, the assay was developed as a two-plate protocol in a 384-well format. For compound testing, the cells were seeded at a density of 4000 (Rat-1_PI3Kdelta), 7500 (Rat-1_PI3Kalpha), or 6200 (Rat-1_PI3Kbeta) cells in 20 ul complete growth medium into cell culture treated 384-well plates and were grown at 37°C / 5 % C02 / 90 % humidity for 24 h. Shortly before compound transfer, the complete medium was removed, 30 ul assay buffer (DMEM high glucose, 1x MEM NEAA, 10 mM HEPES, 2 mM L-glutamine, 0.1 % (w/v) BSA) was added and 10 ul of the compound predilutions were transferred to the cells. For testing after February 2010, assay buffer was substituted for complete growth medium, which revealed similar results (data not shown). After treatment with compound for 1 h, the cells were lysed by the addition of 20 ul lysis buffer supplemented with 0.24 % (w/v) BSA. Detection of p-AKT(Ser473) was performed with the the SureFire p-Akt 1/2 (Ser473) Assay Kit according to the manufacturer's instructions using 5 ul of cell lysate in a total detection volume of 12 ul.
IC50 values of the percentage inhibition of each compound at 8 concentrations (usually 10, 3.0, 1.0, 0.3, 0.1 , 0.030, 0.010 and 0.003 μΜ) n=2 were derived by fitting a sigmoidal dose-response curve to a plot of assay readout over inhibitor concentration as described. All fits were performed with the program XLfit4 (ID Business Solutions, Guildford, UK).
Cellular assay for mTOR
A cell based assay (384-well format) was developed for determination of compound effects on cellular mTOR activity in MEF (mouse embryo fibrobrasts) cells derived from mice lacking TSC1 (Tuberosclerosis Complexl ) a potent suppressor of mTOR activity. Due to lack of TSC1 , mTOR is constitutively activated resulting in permanent phoshorylation of Thr 389 of S6 kinase 1 (S6K1 ) which is one of the downstream targets of mTOR.
Using a SureFire Kit that enables to determine the phosphorylation of Thr389 on the S6K1 an assay was developed, validated and implemented in the Alpha-Screen format that allows the quantitative determination of phospho-T389 of S6K1 in cell lysates.
Treatment of the MEF TSC1-/- cells with mTOR specific (or mTOR pathway-) inhibitors dose-dependently reduced the levels of phospho-T389 on S6K1 allowing calculation of
IC50 values. These were in agreement with those values obtained with the biochemical mTOR ATP-binding assay enabling a quantitative comparison of potency of mTOR inhbitors.
TSC1 -/- MEFs cells (Kwiatkowski, D. J., Zhang, H., Bandura, J. L, Heiberger, K. M., Glogauer, M., el-Hashemite, N., and Onda, H. (2002) Hum. Mol. Genet. 11 , 525-534) were cultured in DMEM high glucose medium supplemented with 10% FBS (Invitrogen), 2mM Glutamine and 1% (w/v) Penicillin/Streptomycin at 37°C, 5% C02.
The SureFire kit for determination of P70S6kinase phosphorylation was purchased from Perkin Elmer (p70S6K p-T389, #TGR70S50K) and the assay was performed according to the instructions of the supplier and according to the generic method for SureFire assays. Shortly, 5 μΙ_ cell lysate per well were transferred to 384-well white proxy-plates (for luminescent readout) and mixed with 7 μΙ_ A and 5 μΙ_ B (final volume: 12 μΙ_). After 3 h incubation in the dark at RT luminescence was read with the Envision Reader (Perkin Elmer). Untreated cells were used as control (high control) and cells treated with 3 μΜ BEZ235 were used as low control. The assay window between the signals obtained for the high and the low controls were defined as 100 % and compound effects were expressed as percent inhibition. IC50 values were calculated from the dose response curves by graphical extrapolation.
The results obtained using the above-described assays are provided in the following tables.
Biochemical PI3Kalpha
PI3Ka / IC50
Example no. [umol
1-1]
1 0.006
2 0.078
3 0.005
4 0.047
5 0.023
6 0.071
7 0.061
8 0.057
9 0.010
10 0.009
1 1 0.017
12 0.008
13 0.006
14 0.007
WO2007/084786
0.094
Example 17
WO2007/084786
0.091
Example 18
WO2007/084786
0.016
Example 85
WO2007/084786
0.327
Example 324
WO2007/084786 0.015 Example 343
Biochemical PI3Kbeta
PI3Kb / IC50
Example no. [umol
1-1]
1 0.009
2 0.096
3 0.007
4 0.159
5 0.031
6 0.460
7 0.110
8 0.067
9 0.015
10 0.005
1 1 0.010
12 0.007
13 0.01 1
14 0.006
WO2007/084786
0.237 Example 17
WO2007/084786
0.236 Example 18
WO2007/084786
0.015 Example 85
WO2007/084786
1.067 Example 324
WO2007/084786
0.027 Example 343
Biochemical PI3Kdelta
PI3Kd / IC50
Example no. [umol
1-1]
1 0.003
2 0.027
3 0.004
4 0.066
5 0.147
6 0.079
7 0.041
8 0.026
9 0.010
10 0.031
1 1 0.014
12 0.004
13 0.003
14 0.016 0.848 Example 17
WO2007/084786
1.978 Example 18
WO2007/084786
0.024 Example 85
WO2007/084786
1.219 Example 324
WO2007/084786
0.110 Example 343
Biochemical PI3Kgamma
PI3Kg / IC50
Example no. [umol
1-1]
1 0.092
2 5.8
3 0.110
4 4.5
5 3.5
6 7
7 3
8 0.580
9 0.230
10 0.343
1 1 0.102
12 0.135
13 0.100
14 0.027
WO2007/084786
3.36 Example 17
WO2007/084786
7.35 Example 18
WO2007/084786
0.315 Example 85
WO2007/084786
4.46 Example 324
WO2007/084786
0.170 Example 343 Binding assay mTor mTor / IC50
Example no. [umol
1-1]
1 0.251
2 2.8
3 0.850
4 >9.7
5 2.25 6 4.7
7 2.7
8 0.960
9
10 1.01
1 1 0.870
12 0.750
13 0.230
14 0.490
WO2007/084786
5.06
Example 17
WO2007/084786
3.3
Example 18
WO2007/084786
2.35
Example 85
WO2007/084786
>9.55 Example 324
WO2007/084786
>10
Example 343
Cellular assay PI3Kalpha
Rat1-PI3Ka /
Example no. IC50 [umol I- 1]
1 0.031
2 1.07
3 0.074
4 0.597
5 0.434
6 0.930
7 0.452
8 0.173
9 0.029
10 0.085
1 1 0.032
12 0.063
13 0.126
14 0.046
WO2007/084786
0.369 Example 17
WO2007/084786
0.606 Example 18
WO2007/084786
0.127
Example 85
WO2007/084786
1.730
Example 324
WO2007/084786
>10
Example 343 Cellular assay PI3Kbeta Rat1-PI3Kb /
Example no. IC50 [umol I- 1]
1 0.020
2 0.751
3 0.033
4 0.757
5 0.201
6 0.420
7 0.430
8 0.026
9 0.254
10 0.023
1 1 0.026
12 0.064
13 <0.003
14 0.007
WO2007/084786
1.54 Example 17
WO2007/084786
1.58 Example 18
WO2007/084786
0.156 Example 85
WO2007/084786
5.31 Example 324
WO2007/084786
>10 Example 343
Cellular assay PI3Kdelta
Rat1-PI3Kd /
Example no. IC50 [umol I- 1]
1 0.01 13
2 0.105
3 0.006
4 0.298
5 0.119
6 0.144
7 0.123
8 0.028
9 0.01 1
10 0.022
1 1 0.020
12 0.004
13 <0.003
14 0.004
WO2007/084786
1.04 Example 17
WO2007/084786
1.47 Example 18 0.139
Example 85
WO2007/084786
6.54
Example 324
WO2007/084786
0.105
Example 343
Cellular assay mTOR mTOR
Example no. 36K(T389) TSCI ko
/ IC50 [umol 1-1]
1 0.243
2 >2.27
3 0.159
4 >2.27
5 0.371
6 >2.27
7 >2.27
8 >4.55
9
10 0.221
1 1 0.747
12 0. 274
13 1.07
14 0.724
WO2007/084786
2.12
Example 17
WO2007/084786
>2.27
Example 18
WO2007/084786
1.03
Example 85
WO2007/084786
>2.27
Example 324
WO2007/084786
>2.27
Example 343 Photostability
Samples investigated for light stability were treated in a light stability chamber (Atlas CPS+, Serial Number 0704013). Solutions of 1.0mg/ml in ethanol were prepared for each molecule and aliquots of 0.5mL were dispensed into suitable micro tubes. All measurements were done in duplicate and compared to a reference wrapped in aluminium foil during light exposure. Solutions were exposed to 19620kJ/m2 over 13h.
Samples were kept at 15°C during the experiment. After treatment in the light chamber, the solutions were analyzed by UPLC (UPLC 1 , experimental part) at 254 nm. The peak areas were automatically integrated, and the degradation percentage calculated as the difference between the corresponding peak area percentage of the reference sample and the average peak area percentage of the exposed samples (duplicate).
The data obtained using this method is shown in the following table:
Figure imgf000073_0001
Anti-proliferative inhibition on the proliferation of cell lines
Cells and cell cultures used for compound profiling
The SCL-1 and SCC12B2 are human cutaneous squamous cell carcinoma (SCC) cell lines derived from naturally occurring, poorly differentiated SCCs. The SCL-1 cell line was originally established in the lab of N. Fusenig at the Cancer Reserach Center in
Heidelberg, and its growth characteristics in vitro in comparison to normal keratinocytes were described previously (Neely et al 1991 ). The SCC12B2 cell line was established as described previously (Rheinwald & Beckett 1981 ) from the facial skin of a male transplant patient who received immunosuppressive therapy for 7 years. The human SCC cell line Detroit562 was obtained from American Tissue Culture Collection (ATCC).
Detroit562 is referred to as Head&Neck squamous cell carcinomas (HNSCC) and was derived from a pharyngeal SCC tumor. The Detroit562 cell line bears the activating mutation H1047R of the PIK3CA gene. This mutation is known as one of the "hotspot" mutations of p1 10a -chain rendering this kinase isoform constitutively active and stimulating the Akt/mTOR pathway independent of growth factor receptor activation. All SCC cell lines were maintained and cultured in Dulbecco modified Eagle's medium (DMEM) medium (Gibco; catalog number: #10938) which was further supplemented with 5%FCS (Gibco; #16000-044), 100μΜ sodium-pyruvat (Gibco; #11360-039), 10mM HEPES (Gibco; #91002-066), 50U/ml penicillin and 50μg/ml streptomycin mixture
(Gibco;#15070-063), and 2mM L- glutamine (Gibco; #25030- 024). All concentrations are given as final concentrations. Cell were propagated in Corning Costar flasks with ventilation caps, using either of two flask sizes with 75cm2 (Corning; #430641 ), or 150cm2 (Corning, #430825) growth areas. The cell cultures were routinely maintained at 37° C in an atmosphere containing 5% C02 and 80% relative humidity (Heraeus type).
Measurement of cell proliferation
Cells of SCC or keratinocyte lines (Detroit562, SCC12B2, SCL1 , HaCaT) were used for the proliferation assays when they had reached about 80% to 90% confluency. Cells were then harvested after trypsin-mediated dislodgement from culture flasks, washed in culture medium containing 10% FCS, counted in a hemocytometer and diluted complete culture medium with 5% FCS to obtain a cell density of 5x104 cells/ml. 100μΙ of this cell suspension (e.g. 5000 cells) were transferred into each well of a 96-well white walled tissue culture plate (Corning-Costar article #3917). Cells were then allowed to settle by placing them in the C02 incubator for 45 to 60 minutes. Subsequently, a volume of 100μΙ of culture medium containing twice the desired final concentration of the test compound was added to each well of quadruplicate wells. One quadruplicate received 100μΙ culture medium without test article as control (indicated in the data figures with the abbreviation no cpd on the x-axis). The cell cultures were then incubated in the presence or absence of the test compounds for a total of 26 to 28 hours. The cell proliferation was determined on the basis of incorporation of bromodesoxy-uridin (BrdU) into cellular DNA using the chemiluminescent BrdU Cell Proliferation ELISA (Roche article # 1 669 915 001 ).
Briefly, the BrdU reagent was diluted 1 :100 with complete culture medium to obtain a concentration of 100μΜ BrdU. From this solution, 20μΙ were added to each well and the cell culture was further incubated for 16 to 18 hours at 37°C at 5% C02. The proliferation assay was stopped after 44 to 46 hours by complete removal of the culture medium and addition of 200μΙ fixing solution (provided with the ELISA kit) for 30 minutes at room temperature. All further incubations, washings and assay development procedures were performed exactly as described in the ELISA assay manual provided by the
manufacturer (Roche). Incorporation of BrdU into the DNA was detected by BrdU- specific antibodies and quantified on the basis of an antibody-coupled luciferase mediated signal generation. The luminescence emission was measured in a Victor light 1420 Luminescence counter, (Perkin Elmer) and expressed as relative luminescence units (e.g. data points given as RLU/s) per second. The data points of each well were transferred to the Windows® Excel spreadsheets for calculation of mean and standard deviation values. These values were plotted using the sigmoidal curve fitting function available in the Origin 7.5® software.
Anti-proliferative potency of compounds measured in SCC cell linesThe data obtained using these SCC and keratinocyte cell lines are shown in the following table. All values indicating the anti-proliferative potency represent the nanomolar IC50
concentrations obtained in two independent assays using either SCC cell lines SCL-1 , SCC12B2, Detroit562 or the HaCaT keratinocyte cell line:
Figure imgf000075_0001
All values are nanomolar IC50 concentrations
Skin penetration The skin penetration/permeation properties of one representative compound of the present invention were tested as follows:
In vitro test to determine skin penetration and permeation properties The compound was applied as 0.5% solutions in propylene glycol mixed with either ethanol or oleylalcohol to pig skin mounted in static Franz-type diffusion cells. At the end of a 48 hours exposure time, drug concentrations were measured in the skin (after removal of stratum corneum) and in the receiver. The receiver solution is a mixture of two volume parts of phosphate-buffered saline (PBS) and one volume part of fetal calf serum (FCS).
Skin penetration and permeation in vitro
Figure imgf000076_0001
Skin concentrations are given as mean ± standard deviation of quadruplicate determinations.
(a): skin was derived from 4 months old farm pigs (Landrace X Deutsches Edelschwein)
(b) : 7 volume parts of propylene glycol (PG) mixed with of 3 volume parts of ethanol
(c) : 9 volume parts of PG mixed with 1 volume part of oleylalcohol (OA)
The compound of example 1 penetrates well into pig skin in vitro, while permeation rate through pig skin is low, indicating a low systemic exposure. Pig skin is similar to human skin regarding barrier function and architecture.
In vivo test to determine penetration into dermis of topically treated pigs
Small skin areas (4cm2) on the dorsolateral back of young domestic pigs were treated topically with 0.5% solutions or suspensions at different time intervals (2 and 24 h) prior to drug level determination. In this experiment, 4 pigs were treated, and the compound administered in the respective formulation at 4 different sites. Skin flaps with the treated sites in the centre were dissected and removed. The skin flaps were spread, and heated metal blocks placed on the test sites for 1 minute to induce separation of epidermis from the dermis. After removal of the loosened epidermal sheets, 1 mm thick dermal sheets were prepared from the treated, de-epidermized skin with a dermatome. From these sheets 6mm punch samples (6 mm 0) were collected and analysed for test compound concentration by LC/MS. The procedure described was done with careful avoidance of contamination of the dermal samples with compound attached superficially to the epidermis.
The following table provides dermal concentrations of the compound of example 1 in pig dermis when applied epicutaneously in the identified formulations. The data table provides the mean ± standard error of the mean of 8 determinations (e.g. eight skin samples analyzed for each time point).
Skin PK in vivo in pigs
Figure imgf000077_0001
Mean ± standard error mean of eight determinations are g
Tween®80: polyoxyethylenesorbitan monooleate
OA: oleylalcohol
PG: propylene glycol
EtOH : ethanol
HPMC: hydroxypropylmethylcellulose The compound of example 1 penetrates well into pig skin reaching the dermis in vivo after a single application.

Claims

What is claimed is:
1. A compound of the formula (I ) and/or a pharmaceutically acceptable salt and/or solvate thereof,
Figure imgf000078_0001
(I)
wherein,
R1 is methyl, ethyl or hydroxymethyl;
R2 is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC5-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position,
or
pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC5-alkoxy, hydroxy-C2-C4-alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position,
or
a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F;
and
R3 is H or methyl.
2. A compound according to claim 1 , of formula (lb)
Figure imgf000079_0001
(lb).
3. A compound according to claim 1 or claim 2, wherein
R2 is phenyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, CrC5-alkoxy, hydroxy-C2-C4- alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position.
A compound according to claim 1 or claim 2, wherein
R2 is pyridyl, which is unsubstituted or substituted in meta and/or para positions by 1 or 2 substituents independently selected from D, F or methoxy for the meta position and from D, F, methoxy, C-i-C5-alkoxy, hydroxy-C2-C4- alkoxy or Ci-C2-alkoxy-C2-C4-alkoxy for the para position. 5. A compound according to claim 1 or claim 2, wherein
R2 is a 5 membered monocyclic heteroaryl, containing 2 to 3 heteroatoms selected from N, O or S, which is unsubstituted or substituted by 1 to 2 substituents independently selected from D or F. 6. A compound according to any one of claims 1 to 5, wherein
R1 is methyl.
A compound according to any one of claims 1 to 5, wherein
R1 is ethyl.
8. A compound according to any one of claims 1 to 5, wherein
R1 is hydroxymethyl.
9. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1 , selected from
(4S,5R)-3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-methyl- 5-th iazol-2-yl-oxazol idin-2-one,
(4S 5S*)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5- (4-methoxyphenyl)oxazolidin-2-one,
(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-(hydroxy- methyl)-5-(4-methoxyphenyl)oxazolidin-2-one,
(4S*,5R*)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5- phenyloxazolidin-2-one,
(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-methyl-5- phenyloxazolidin-2-one,
(4R 5R*)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5- (3-methoxyphenyl)oxazolidin-2-one,
(4S,5R)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-ethyl-5- (thiazol-2-yl)oxazolidin-2-one,
3-(2'-amino-2-morpholin-4-yl-4' rifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-ethyl-5-pyridin-3 yl-oxazolidin-2-one,
3-(2'-amino-2-morpholin-4-yl-4' rifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-methyl-5-pyridin 3-yl-oxazolidin-2-one,
(4S,5S)-3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4- hydroxymethyl-5-phenyl-oxazolidin-2-one,
(4S,5S)-3-(2'-amino-2-morpholin-4-yl-4'-trifluoromethyl-[4,5']bipyrimidinyl-6-yl)-4-methyl- 5-th iazol-2-yl-oxazol idin-2-one,
(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-
(hydroxymethyl)-5-(4-(2-methoxyethoxy)phenyl)oxazolidin-2-one,
(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-5-(4-(2- hydroxyethoxy)phenyl)-4-(hydroxymethyl)oxazolidin-2-one or
(4S,5S)-3-(2'-amino-2-morpholino-4'-(trifluoromethyl)-[4,5'-bipyrimidin]-6-yl)-4-
(hydroxymethyl)-5-(4-(3-hydroxypropoxy)phenyl)oxazolidin-2-one.
10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
11. A combination comprising a therapeutically effective amount of a compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, and one or more therapeutically active co-agents.
12. A method of treating a subject comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 9.
13. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use as a medicament.
14. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use in the treatment of non-melanoma skin cancers, pre- malignant stages of non-melanoma skin cancers or other hyperproliferative skin disorders caused by dysregulation of skin fibroblasts.
15. Use of a compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of non- melanoma skin cancers, pre-malignant stages of non-melanoma skin cancers or other hyperproliferative skin disorders caused by dysregulation of skin fibroblasts.
PCT/IB2013/060052 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives WO2014072956A1 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
MA38076A MA38076A1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
IN2912DEN2015 IN2015DN02912A (en) 2012-11-12 2013-11-11
AU2013343022A AU2013343022B2 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
DK13795867.4T DK2922848T5 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
CA2890942A CA2890942C (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
RS20170882A RS56336B1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
AP2015008347A AP2015008347A0 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
ES13795867.4T ES2641820T3 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
EP17157570.7A EP3199158B1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives for use in the treatment of skin fibrosis, scleroderma, hypertrophic scars or keloids
CU2015000050A CU24365B1 (en) 2012-11-12 2013-11-11 DERIVATIVES OF OXAZOLIDIN-2-ONA-PYRIMIDINE
JP2015541289A JP6262245B2 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one pyrimidine derivatives
SG11201503447QA SG11201503447QA (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
KR1020157011951A KR102153763B1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
EP13795867.4A EP2922848B1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
BR112015010136A BR112015010136A2 (en) 2012-11-12 2013-11-11 oxazolidin-2-one-pyrimidine derivatives
LTEP13795867.4T LT2922848T (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
PL13795867T PL2922848T3 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
EA201590929A EA027987B1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
MX2015005914A MX363436B (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives.
NZ706591A NZ706591A (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
UAA201502809A UA114001C2 (en) 2012-11-12 2013-11-11 OXAZOLIDINE-2-ON-PYRIMIDINE DERIVATIVES
CN201380052670.1A CN104718204B (en) 2012-11-12 2013-11-11 The ketone pyrimidine derivatives of oxazolidine 2
SI201330782T SI2922848T1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives
TNP2015000120A TN2015000120A1 (en) 2012-11-12 2015-03-27 Oxazolidin-2-one-pyrimidine derivatives
ZA2015/02175A ZA201502175B (en) 2012-11-12 2015-03-30 Oxazolidin-2-one-pyrimidine derivatives
IL238239A IL238239A (en) 2012-11-12 2015-04-12 Oxazolidin-2-one-pyrimidine derivatives
PH12015501053A PH12015501053B1 (en) 2012-11-12 2015-05-12 Oxazolidin-2-one-pyrimidine derivatives
CR20150248A CR20150248A (en) 2012-11-12 2015-05-12 DERIVATIVES OF OXAZOLIDIN-2-ONA-PYRIMIDINE
HK15109748.9A HK1209108A1 (en) 2012-11-12 2015-10-06 Oxazolidin-2-one-pyrimidine derivatives -2--
HRP20171425TT HRP20171425T1 (en) 2012-11-12 2017-09-20 Oxazolidin-2-one-pyrimidine derivatives
CY20171101014T CY1119391T1 (en) 2012-11-12 2017-09-27 OXAZOLIDIN-2-ONY-PYRIMIDINE PRODUCTS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725113P 2012-11-12 2012-11-12
US61/725,113 2012-11-12

Publications (1)

Publication Number Publication Date
WO2014072956A1 true WO2014072956A1 (en) 2014-05-15

Family

ID=49667527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/060052 WO2014072956A1 (en) 2012-11-12 2013-11-11 Oxazolidin-2-one-pyrimidine derivatives

Country Status (43)

Country Link
US (3) US9296733B2 (en)
EP (2) EP3199158B1 (en)
JP (1) JP6262245B2 (en)
KR (1) KR102153763B1 (en)
CN (1) CN104718204B (en)
AP (1) AP2015008347A0 (en)
AR (1) AR093408A1 (en)
AU (1) AU2013343022B2 (en)
BR (1) BR112015010136A2 (en)
CA (1) CA2890942C (en)
CL (1) CL2015001202A1 (en)
CO (1) CO7380758A2 (en)
CR (1) CR20150248A (en)
CU (1) CU24365B1 (en)
CY (1) CY1119391T1 (en)
DK (1) DK2922848T5 (en)
EA (2) EA029714B1 (en)
EC (1) ECSP15025093A (en)
ES (1) ES2641820T3 (en)
HK (1) HK1209108A1 (en)
HR (1) HRP20171425T1 (en)
HU (1) HUE034492T2 (en)
IL (1) IL238239A (en)
IN (1) IN2015DN02912A (en)
JO (1) JO3334B1 (en)
LT (1) LT2922848T (en)
MA (1) MA38076A1 (en)
MX (1) MX363436B (en)
MY (1) MY174239A (en)
NZ (1) NZ706591A (en)
PE (1) PE20151006A1 (en)
PH (1) PH12015501053B1 (en)
PL (1) PL2922848T3 (en)
PT (1) PT2922848T (en)
RS (1) RS56336B1 (en)
SG (1) SG11201503447QA (en)
SI (1) SI2922848T1 (en)
TN (1) TN2015000120A1 (en)
TW (1) TWI608005B (en)
UA (1) UA114001C2 (en)
UY (1) UY35128A (en)
WO (1) WO2014072956A1 (en)
ZA (1) ZA201502175B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019087158A2 (en) 2017-11-06 2019-05-09 Novartis Ag Formulation comprising oxazolidin-2-one-pyrimidine derivative
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
US11918586B2 (en) 2016-05-18 2024-03-05 Torqur Ag Treatment of skin lesions

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24269B1 (en) 2011-09-27 2017-08-08 Novartis Ag 3- PIRIMIDIN- 4-IL- OXAZOLIDIN- 2- INHIBITING WAVES OF THE MUTANT HDI
UY34632A (en) 2012-02-24 2013-05-31 Novartis Ag OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
MX355945B (en) 2013-03-14 2018-05-07 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh.
EP3352755A4 (en) 2015-09-24 2019-04-03 Drexel University Novel compositions and methods for treating or preventing dermal disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2007084786A1 (en) 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB581334A (en) 1943-09-29 1946-10-09 Francis Henry Swinden Curd New pyrimidine compounds
JPS4921149B1 (en) 1970-12-28 1974-05-30
JPS4921148B1 (en) 1970-12-28 1974-05-30
DE2341925A1 (en) 1973-08-20 1975-03-06 Thomae Gmbh Dr K 2,4, (opt.5-), 6-substd. pyriminidines as antithrombic agents - e.g. 6-methyl-5-nitro-2-piperazino-4-thiomorpolino-pyrimidine
AT340933B (en) 1973-08-20 1978-01-10 Thomae Gmbh Dr K PROCESS FOR THE PRODUCTION OF NEW PYRIMIDE DERIVATIVES AND THEIR ACID ADDITIONAL SALTS
US4994386A (en) 1987-07-13 1991-02-19 Pharmacia Diagnostics, Inc. Production of HBLV virus in the HSB-2 cell line
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
EP0330263A1 (en) 1988-02-25 1989-08-30 Merck & Co. Inc. Piperazinylalkylpyrimidines as hypoglycemic agents
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
KR950007756B1 (en) 1990-07-03 1995-07-14 미쓰이세끼유 가가꾸고오교오 가부시끼가이샤 Pyrimidine compound and pharmacentically acceptable salt thereof
KR100275300B1 (en) 1995-04-13 2000-12-15 고바야시 유키오 Novel 4,6-diarylpyrimidine derivatives and salts thereof
JP3734907B2 (en) 1996-12-19 2006-01-11 富士写真フイルム株式会社 Development processing method
EP1020462B1 (en) 1997-07-24 2004-02-11 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agent containing the same as active ingredient
JPH11158073A (en) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd Adenosine a3 antagonist
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6150362A (en) 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
EP0930302B1 (en) 1998-01-16 2003-04-02 F.Hoffmann-La Roche Ag Benzosulfone derivatives
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP4533534B2 (en) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Inhibitor of glycogen synthase kinase 3
EP1144390A2 (en) 1999-01-22 2001-10-17 Amgen Inc., Kinase inhibitors
US6495558B1 (en) 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
JP2003523942A (en) 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド SRC kinase inhibitor compounds
CA2376951A1 (en) 1999-06-30 2001-01-04 Peter J. Sinclair Src kinase inhibitor compounds
JP2003503351A (en) 1999-06-30 2003-01-28 メルク エンド カムパニー インコーポレーテッド SRC kinase inhibitory compounds
JP2003505384A (en) 1999-07-15 2003-02-12 ファーマコピーア，インコーポレーティッド Bradykinin B1 receptor antagonist
JP2001089452A (en) 1999-09-22 2001-04-03 Sankyo Co Ltd Pyrimidine derivative
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
CN100355751C (en) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2-substd. 4-heteroaryl-pyrimidines and their use in treatment of proliferative disorders
ES2360933T3 (en) 2000-04-27 2011-06-10 Astellas Pharma Inc. CONDENSED HETEROARILO DERIVATIVES.
KR100711042B1 (en) 2000-04-28 2007-04-24 다나베 세이야꾸 가부시키가이샤 Cyclic compounds
CA2409762A1 (en) 2000-06-23 2002-01-03 Donald J.P. Pinto Heteroaryl-phenyl substituted factor xa inhibitors
WO2002020495A2 (en) 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP4105948B2 (en) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazole compounds useful as protein kinase inhibitors
SE0004053D0 (en) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
KR100909665B1 (en) 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 Pyrazole Compounds Useful as Protein Kinase Inhibitors and Pharmaceutical Compositions Comprising the Same
EP1363890A4 (en) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc Melanocortin-4 receptor binding compounds and methods of use thereof
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
CA2448626A1 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
WO2002102313A2 (en) 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Pyrimidine inhibitors of phosphodiesterase (pde) 7
US6603000B2 (en) 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003078427A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
AU2003225800A1 (en) 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
WO2003078423A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Compositions useful as inhibitors of protein kinases
WO2003077921A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azinylaminoazoles as inhibitors of protein kinases
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
US20040171073A1 (en) 2002-10-08 2004-09-02 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
PL377821A1 (en) 2002-11-21 2006-02-20 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
CN101468965A (en) 2003-03-24 2009-07-01 默克公司 Biaryl substituted 6-membered heterocyles as sodium channel blockers
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
CA2520323C (en) 2003-04-09 2013-07-09 Exelixis, Inc. Tie-2 modulators and methods of use
WO2005009977A1 (en) 2003-07-15 2005-02-03 Neurogen Corporation Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands
JP2007534624A (en) 2003-07-16 2007-11-29 ニューロジェン・コーポレーション Biaryl piperazinyl-pyridine analogues
AR045944A1 (en) 2003-09-24 2005-11-16 Novartis Ag ISOQUINOLINE DERIVATIVES 1.4-DISPOSED
DE602005024382D1 (en) 2004-04-13 2010-12-09 Astellas Pharma Inc POLYCYCLIC PYRIMIDINES AS CALIUMIONAL CHANNEL MODULATORS
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
MX2007006230A (en) * 2004-11-30 2007-07-25 Amgen Inc Quinolines and quinazoline analogs and their use as medicaments for treating cancer.
JP2008523156A (en) 2004-12-13 2008-07-03 ニューロジェン・コーポレーション Substituted biaryl analogs
US20080045525A1 (en) 2004-12-13 2008-02-21 Rajagopal Bakthavatchalam Piperazinyl-Pyridine Analogues
ATE544748T1 (en) 2004-12-28 2012-02-15 Kinex Pharmaceuticals Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OF CELL PROLIFERATION DISEASES
EP1838703A2 (en) 2005-01-19 2007-10-03 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
CA2599320A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
TW200716594A (en) 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
AU2007204208A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
EP2012794B1 (en) * 2006-04-13 2014-09-17 The Trustees of Columbia University in the City of New York Compositions and intraluminal devices for inhibiting vascular stenosis
AR064571A1 (en) 2006-12-28 2009-04-08 Basf Ag PYRIMIDINES REPLACED IN POSITION 2 BY NITROGEN HETEROCICLES, MEDICINES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME IN THE TREATMENT OF CANCER.
JP2010518107A (en) 2007-02-06 2010-05-27 ノバルティス アーゲー PI3-kinase inhibitors and methods of use thereof
US7957951B2 (en) 2007-03-16 2011-06-07 Robert Bosch Gmbh Address translation system for use in a simulation environment
EA201000092A1 (en) 2007-07-09 2010-06-30 Астразенека Аб TRIPLE-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
EP2591805A1 (en) 2008-03-05 2013-05-15 Novartis AG Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
CN101980708B (en) 2008-03-26 2013-03-13 诺瓦提斯公司 Imidazoquinolines and pyrimidine derivatives as potent modulators of VEGF-driven angiogenic processes
US20110053907A1 (en) 2008-03-27 2011-03-03 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
EP2280948A1 (en) 2008-04-09 2011-02-09 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
RU2538683C2 (en) 2008-10-31 2015-01-10 Новартис Аг COMBINATION OF PHOSPHATIDYL INOSITOL-3-KINASE (PI3K) INHIBITOR AND mTOR INHIBITOR
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010068863A2 (en) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
ES2453474T3 (en) 2009-02-06 2014-04-07 Nippon Shinyaku Co., Ltd. Aminopyrazine derivatives and corresponding medicine
JP5747440B2 (en) 2009-02-06 2015-07-15 住友化学株式会社 Hydrazide compound and its use for pest control
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
PL2432767T3 (en) 2009-05-19 2013-11-29 Dow Agrosciences Llc Compounds and methods for controlling fungi
EP2451802A1 (en) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
TWI393716B (en) 2009-08-04 2013-04-21 Merck Sharp & Dohme Heterocyclic compounds as factor ixa inhibitors
AR077999A1 (en) 2009-09-02 2011-10-05 Vifor Int Ag ANTIGONISTS OF PYRIMIDIN AND TRIAZIN-HEPCIDINE
NZ598808A (en) 2009-09-09 2014-07-25 Celgene Avilomics Res Inc Pi3 kinase inhibitors and uses thereof
EP2509600B1 (en) 2009-12-09 2017-08-02 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
CA2805669C (en) 2010-07-16 2018-08-21 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MX354482B (en) 2010-10-01 2018-03-07 Novartis Ag Star Manufacturing process for pyrimidine derivatives.
JP5856177B2 (en) 2010-10-18 2016-02-09 セレニス セラピューティクス ホールディング エスアー Compounds, compositions and methods useful for cholesterol mobilization
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
RU2013141559A (en) 2011-02-11 2015-03-20 Дана-Фарбер Кэнсер Инститьют, Инк. METHOD FOR INHIBITING HAMARTOMA TUMOR CELL CELLS
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
EP2750670A1 (en) 2011-09-01 2014-07-09 Novartis AG Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone
CU24269B1 (en) 2011-09-27 2017-08-08 Novartis Ag 3- PIRIMIDIN- 4-IL- OXAZOLIDIN- 2- INHIBITING WAVES OF THE MUTANT HDI
CA2851082A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
UY34632A (en) 2012-02-24 2013-05-31 Novartis Ag OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
SG11201406550QA (en) * 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
CA2872541A1 (en) 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
MX369518B (en) 2012-08-16 2019-11-11 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor.
PT2912030T (en) 2012-10-23 2016-11-30 Novartis Ag Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
MX355945B (en) 2013-03-14 2018-05-07 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh.
WO2014141153A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CN103483345B (en) 2013-09-25 2016-07-06 中山大学 PI3K inhibitors of kinases, the pharmaceutical composition comprising it and application thereof
CN103694218B (en) 2013-12-05 2016-04-27 中山大学 Pyrimidine compound, PI3K inhibitor, the pharmaceutical composition comprising PI3K inhibitor and application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2007084786A1 (en) 2006-01-20 2007-07-26 Novartis Ag Pyrimidine derivatives used as pi-3 kinase inhibitors

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"Beilsteins Handbuch der organischen Chemie", SPRINGER-VERLAG, BERLIN
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
"Remington's Pharmaceutical Sciences", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329
BAYASCAS; ALESSI, MOL CELL, vol. 18, no. 2, 2005, pages 143 - 145
CHEN ET AL., BR J DERMATOL, vol. 160, no. 2, 2009, pages 442 - 445
DARIDO ET AL., CANCER CELL, vol. 20, no. 5, 2011, pages 635 - 648
HOUBEN-WEYL: "Methods of Organic Synthesis", vol. 21, 1952, THIEME
HUANG ET AL., SCIENCE, vol. 318, 2007, pages 1744 - 1748
KENIRY; PARSONS, ONCOGENE, vol. 27, 2008, pages 5477 - 5485
KWIATKOWSKI, D. J.; ZHANG, H.; BANDURA, J. L.; HEIBERGER, K. M.; GLOGAUER, M.; EL-HASHEMITE, N.; ONDA, H., HUM. MOL. GENET., vol. 11, 2002, pages 525 - 534
LIU ET AL., NAT REV DRUG DISCOV, vol. 8, 2009, pages 627 - 644
LOUIS F. FIESER; MARY FIESER: "Reagents for Organic Synthesis", vol. 1-19, 1967, WILEY
MAIRA SM; PECCHI S; BRUEGGEN J; HUH K; SCHNELL C; FRITSCH C; NAGEL T; WIESMANN M; BRACHMANN S; DORSCH M, MOL. CANCER THER., 2011
MAIRA SM; STAUFFER F; BRUEGGEN J; FURET P; SCHNELL C; FRITSCH C; BRACHMANN S; CHENE P; DE POVER A; SCHOEMAKER K, MOL CANCER THER., vol. 7, 2008, pages 1851 - 63
MING ET AL., ONCOGENE, vol. 29, no. 4, 2010, pages 492 - 502
SALASCHE, J AM ACAD DERMATOL, vol. 42, 2000, pages 4 - 7
SARBASSOV ET AL., SCIENCE, vol. 307, 2005, pages 1098 - 1101
STAHL; WERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH
T. W. GREENE: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS
VANHAESEBROECK ET AL., ANNU. REV. BIOCHEM, vol. 70, 2001, pages 535
WEE ET AL., PORC NATL ACAD SCI USA, vol. 105, 2008, pages 13057 - 13062
ZHAO; VOGT, ONCOGENE, vol. 27, 2008, pages 5486 - 5496

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11918586B2 (en) 2016-05-18 2024-03-05 Torqur Ag Treatment of skin lesions
WO2019087158A2 (en) 2017-11-06 2019-05-09 Novartis Ag Formulation comprising oxazolidin-2-one-pyrimidine derivative
WO2019087158A3 (en) * 2017-11-06 2019-06-20 Novartis Ag Formulation comprising oxazolidin-2-one-pyrimidine derivative
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Also Published As

Publication number Publication date
CA2890942A1 (en) 2014-05-15
CA2890942C (en) 2021-01-12
ES2641820T3 (en) 2017-11-14
AU2013343022A1 (en) 2015-04-23
MY174239A (en) 2020-04-01
HRP20171425T1 (en) 2017-11-17
TW201427974A (en) 2014-07-16
HK1209108A1 (en) 2016-03-24
NZ706591A (en) 2016-03-31
HUE034492T2 (en) 2018-02-28
CY1119391T1 (en) 2018-02-14
EA027987B1 (en) 2017-09-29
MX2015005914A (en) 2015-09-08
BR112015010136A2 (en) 2017-07-11
RS56336B1 (en) 2017-12-29
CU20150050A7 (en) 2015-11-27
AR093408A1 (en) 2015-06-03
EA201590929A1 (en) 2015-08-31
CL2015001202A1 (en) 2015-07-03
CN104718204A (en) 2015-06-17
ECSP15025093A (en) 2019-03-29
EP2922848B1 (en) 2017-06-28
DK2922848T5 (en) 2017-10-30
US20160168145A1 (en) 2016-06-16
TWI608005B (en) 2017-12-11
EA201790289A1 (en) 2017-06-30
IN2015DN02912A (en) 2015-09-11
LT2922848T (en) 2017-09-25
PH12015501053A1 (en) 2015-07-27
AP2015008347A0 (en) 2015-04-30
MA38076A1 (en) 2018-02-28
PT2922848T (en) 2017-10-05
CU24365B1 (en) 2018-10-04
EA029714B1 (en) 2018-05-31
EP3199158A1 (en) 2017-08-02
US20190382399A1 (en) 2019-12-19
UY35128A (en) 2014-06-30
KR102153763B1 (en) 2020-09-09
CO7380758A2 (en) 2015-09-10
PL2922848T3 (en) 2017-12-29
TN2015000120A1 (en) 2016-06-29
DK2922848T3 (en) 2017-10-09
IL238239A (en) 2017-05-29
MX363436B (en) 2019-03-22
UA114001C2 (en) 2017-04-10
JO3334B1 (en) 2019-03-13
EP2922848A1 (en) 2015-09-30
JP2015536974A (en) 2015-12-24
ZA201502175B (en) 2018-05-30
SG11201503447QA (en) 2015-05-28
AU2013343022B2 (en) 2015-08-20
PE20151006A1 (en) 2015-07-04
JP6262245B2 (en) 2018-01-17
CR20150248A (en) 2015-07-01
EP3199158B1 (en) 2019-04-17
US10202371B2 (en) 2019-02-12
PH12015501053B1 (en) 2015-07-27
SI2922848T1 (en) 2017-10-30
CN104718204B (en) 2017-11-28
KR20150082295A (en) 2015-07-15
US20140135330A1 (en) 2014-05-15
US9296733B2 (en) 2016-03-29

Similar Documents

Publication Publication Date Title
US10202371B2 (en) Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors
US9458177B2 (en) Oxazolidin-2-one compounds and uses thereof
JP6181173B2 (en) Selective PI3K delta inhibitor
CA3077383A1 (en) Substituted pyrimidine piperazine compound and use thereof
CN113773315A (en) Highly selective deuterated inhibitors of cyclin dependent kinase 2(CDK2)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 12015501053

Country of ref document: PH

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13795867

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 238239

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2013343022

Country of ref document: AU

Date of ref document: 20131111

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20157011951

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 38076

Country of ref document: MA

ENP Entry into the national phase

Ref document number: 2890942

Country of ref document: CA

Ref document number: 2015541289

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 000615-2015

Country of ref document: PE

Ref document number: MX/A/2015/005914

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15107787

Country of ref document: CO

Ref document number: CR2015-000248

Country of ref document: CR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015010136

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2013795867

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013795867

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201590929

Country of ref document: EA

Ref document number: IDP00201503496

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 112015010136

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150505